POPULARITY
95 episodes with adrs
40 episodes with adrs
19 episodes with adrs
10 episodes with adrs
7 episodes with adrs
4 episodes with adrs
3 episodes with adrs
4 episodes with adrs
2 episodes with adrs
Confused by all the Disney terms like ADRs, LLs, LLSPs, and Mobile Order? You're not alone! In this episode of Mom Street USA, we're breaking down the Disney Parks language—the key acronyms, abbreviations, and insider terms used at Walt Disney World and Disneyland.
A casual conversation about Equities Common, Preferred and ADRs
- keine anlageberatung - Warren Buffett's Rücktritt, Greg Abel's Potenzial als neuer CEO [01:34](- Moulth wird Berkshire CEO) [02:00](- Apfel im Podcast-Ausblick) [07:22]Das negative US-BIP - Rezessionsindikator, oder verfälschte Daten?[09:30]Sucht Tesler einen neuen CEO?[12:54]Palantier-Ernte[21:33]"Erektionspillen-Vertreiber Him's & Her's"-Ernte[28:42]Zuckerberg/Gesichtsbuch/Meta-Ernte[31:57]META AIMETA Wayfarer/Rayban-DealBuchladen-Ernte[37:39]Winzigweich-Ernte[39:20]Skechers-Buyout & @bäreneule's-Rundgang im werbeisolierten Wohnbau[45:10]Drill Baby, Drill! Podcast-Ausblick auf die Ölpreise & verkehrte Kryptoambitionen[47:47]FX - Intervention in Taiwan & HK zum Dollar-Peg, Haier-Arbitrage zum Zweiten[50:37](- Freigeldfehler bei ADRs? [53:06])CSGO/CS2-Items als Alternativinvestment[57:52]Steam Summer Sale-Arbitrage & Bananenökonomie[1:16:00]Kommt nun der finale Krypto-Run? Kommt nun der legendäre Mauerstraßen-Teppichzieher (nein)[1:18:20]Warum investiert man in Seglermichi-Strategie?[1:22:26]
In this episode of Good Morning Hospitality, Wil Slickers, Brandreth Canaley, Michael Goldin, and Jamie Lane break down Airbnb's Q1 2025 results, highlighting slowing growth in the U.S. and a surge in international markets. The team covers the shift in nights and experiences booked, record-high ADRs, and what CEO Brian Chesky means when he says Airbnb is nearing the "end of the beginning." We also unpack the key takeaways from Booking Holdings (NASDAQ: BKNG) and Expedia Group's Q1 earnings—what their results say about the state of online travel, how each platform is investing in AI, and where they're pulling back. Plus, we explore the macro trends driving travel this summer and why all three OTAs are bracing for softer U.S. demand. This one's packed with insights for operators, investors, and tech vendors across travel and hospitality. ---- Good Morning Hospitality is part of the Hospitality.FM Multi-Media Network and is a Hospitality.FM Original The hospitality industry is constantly growing, changing, and innovating! This podcast brings you the top news and topics from industry experts across different hospitality fields. Good Morning Hospitality publishes three thirty-minute weekly episodes: every Monday and Wednesday at 7 a.m. PST / 10 a.m. EST and every Tuesday at 8 a.m. CET for our European and UK-focused content. Make sure to tune in during our live show on our LinkedIn page or YouTube every week and join the conversation live! Explore everything Good Morning Hospitality has to offer: • Well & Good Morning Coffee: Enjoy our signature roast—order here! • Retreats: Join us at one of our exclusive retreats—learn more and register your interest here! • Episodes & More: Find all episodes and additional info at GoodMorningHospitality.com Thank you to all of the Hospitality.FM Partners that help make this show possible. If you have any press you want to be covered during the show, email us at goodmorning@hospitality.fm Learn more about your ad choices. Visit megaphone.fm/adchoices
Should the United States delist Chinese stocks? At first thought with all the craziness of the trade war it sounds like delisting all the Chinese companies from the American stock markets may be a good idea. It is important to know that there are 286 Chinese companies listed on major US stock exchanges. You'll recognize some of the names like Alibaba, Baidu and JD.com. It is estimated by analysts at Goldman Sachs that US institutional investors currently own about $830 billion worth of Chinese stocks. That is more than two times what the Chinese own of US stocks as that is estimated around $370 billion. But a quick sell off could bring down stock valuations and make it difficult to get out of many of these stocks on both sides. An important piece of information I brought up a couple years ago was the Accountable Act which came to be in 2020. This allows the Securities Exchange Commission to ban foreign companies from trading if American regulators are not allowed to inspect the auditors for three years in a row. I always worry about Chinese companies because of what I call government accounting. They are not held to the same accounting standards there and I believe companies may list financial statements based on what the government tells them. There have been some Chinese companies that delisted themselves rather than going through an audit. I think that tells you quite a bit. My feeling is we should not delist all the Chinese stocks that trade on American stock exchanges under what is known as ADRs, but be sure that the Chinese companies have the same transparency as American companies when it comes to their financial statements. If we can't get that transparency, then those companies should be delisted. Jobs report shows more evidence the economy is in good shape US nonfarm payrolls grew by 177k in the month of April, which easily topped the estimate of 133k. Jobs remained robust in health care as the sector added 51k jobs in the month of April and employment in transportation and warehousing and financial activities was also strong as the groups added 29k and 14k jobs respectively in the month. Other categories like construction, manufacturing, leisure and hospitality, and retail trade saw little or no change in payrolls, while government declined by 9k jobs in the month. Government jobs are now down by 26k since January, but remember employees on paid leave or receiving ongoing severance pay are still counted as employed. This likely means we will continue to see losses accelerate in this category as the year continues. Negatives in the report included the fact that employment numbers were revised down by a total of 58k in the previous two months. Also, April's reading was lighter than March's reading of 185k, but considering the unemployment rate remains at 4.2%, I still see these jobs gains as impressive, especially with all the negativity that people have been discussing. With that said, I still do anticipate weaker numbers in terms of the payroll additions in future months, but if the unemployment rate remains low I don't see that as a problem. On the inflation front, we also got good news with average hourly earnings rising just 3.8%. I see this as a healthy increase that does not put pressure on inflation like when wages were growing over 5% in 2022. Job openings look problematic on the surface In the March Job Openings and Labor Turnover Survey, job openings totaled 7.2 million. This was below February's reading of 7.5 million and the estimate, which also stood at 7.5 million. This is still not super concerning to me. We tend to forget how strong the labor market has been and while we continue to see a softening, there is plenty of room before I see cause for concern. Just for reference, job openings in 2019 averaged approximately 7.2 million, in 2018 they averaged approximately 6.8 million, and in 2017 they averaged approximately 6.2 million. Compare that to where we are today and that should give you more comfort. Another area I saw as positive in the report was the fact that quits totaled 3.3 million, which produced a quit rate of 2.1%. This is important because if people were truly concerned about a major slowdown and thought they would not be able to find work elsewhere, I don't believe they would be quitting their jobs. These quit numbers are still quite close to 2019 levels, which many considered as a very strong economy. That year quits averaged approximately 3.5 million and there was an average quit rate of about 2.3%. Also in the report, we saw layoffs remained quite low at 1.6 million. Back in 2019, layoffs averaged around 1.8 million per month. There is no doubt that uncertainty remains and that will have some impact on businesses and their hiring plans, but in terms of it pushing the economy into a major recession, since we are coming from such a healthy level, I just don't see that happening. Are we in the middle of a recession? The first reading of Q1 GDP showed a decrease of 0.3%. A recession is generally defined as two consecutive quarters of declining GDP, so some may argue we are half way there. Let us not forget in 2022 we did see two consecutive quarters of declining GDP as Q1 declined 1.4% and Q2 showed an advance estimate that was down 0.9%. After further research the second quarter ended up seeing a total reversal and it is now reported to have actually grown by 0.3%. Even with the difficult start, that year ended with a 2.1% growth rate. We also can't forget that the National Bureau of Economy Research (NBER) makes the official call on recession and they use a broader set of indicators that led them not to declare a recession in 2022. I say all of this because I still believe even if we hit a technical recession, if employment remains strong, I don't believe we would have an “official” recession. I am still unsure that we will even see Q2 GDP decline and we could also see revisions to Q1 that lift it to a positive reading. I say this because if you look at the actual underlying numbers in the report, it is not nearly as bad as the headline decline. On the positive front, consumer spending actually grew 1.8% in the quarter as services showed a nice increase of 2.4%. Also, private domestic investment saw a surge of 21.9%, this was led by investments in equipment as they grew 22.5% in the quarter. You might be asking with numbers like these how did we see a negative GDP? To start, government spending fell 1.4% in the quarter. This was led by a decline of 5.1% in spending by the federal government. The group as a whole ended up subtracting 0.25% from the headline GDP number. While this was impactful, the real reason for the decline in GDP was trade. Companies were trying to get ahead of looming tariffs and imports surged 41.3%. This compared to an increase of just 1.8% for exports. The huge discrepancy caused the trade component of GDP to decrease the headline number by 4.83%! While the economy is no doubt digesting these trade conversations and the tariffs, I still believe the economy is in alright shape when you look at the underlying numbers. I did also want to mention more good news on inflation as the March headline PCE showed an increase of 2.3%, which compares to last month's reading of 2.7% and core PCE came in at just 2.6%, which was a nice decline from February's reading of 3.0%. I believe these numbers will likely increase with the tariffs, but underlying inflation looks to be quite healthy. Financial Planning: Protecting Yourself from Home Title Theft Home title theft is a type of real estate fraud where someone illegally transfers the ownership of your home by forging your name on title documents. This is often done using stolen personal information to file fraudulent deeds with the county recorder's office. Once the title appears to be in their name, the thief may try to take out loans against the property, sell it to an unsuspecting buyer, or use it in other schemes that could put your home and finances at risk. This crime can go undetected for months if property owners aren't actively monitoring their title. Having a mortgage or HELOC on your house can make it more difficult for a thief to steal your title since the bank has a lien against the property, but it is still possible. There are private companies that charge monthly fees to alert you of changes to your home title, but they do not prevent the title from being stolen. You can also purchase home title insurance that will help pay for legal fees if you have to go to court if your title is stolen. Homeowners in San Diego County can access a free alternative called “Owner Alert”. Jordan Marks who is the San Diego County Assessor/Recorder/County Clerk was behind this, and it is a great benefit that all San Diego property owners should take advantage of. This service works by notifying you by email whenever a document is recorded against your property, helping you catch potential fraud early. Signing up is simple and can be done on the San Diego County Assessor's website. You just need your name, email address, and parcel number and it provides the same type of monitoring offered by paid services, making it unnecessary to spend money for peace of mind when this tool is already available for free. Companies Discussed: Zimmer Biomet Holdings, Inc. (ZBH), Take-Two Interactive Software, Inc. (TTWO), Northrop Grumman Corporation (NOC)Alphabet Inc. (GOOG)
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
Today's sponsor is Freed AI! Freed's AI medical scribe listens, transcribes, and writes notes for you. Over 15,000 healthcare professionals use Freed and you should too! Learn more here! Prednisone is a commonly used medication for its antiinflammatory and immunosuppressive action. On this episode I discuss prednisone pharmacology, ADRs, and much more. In the episode, I discuss how prednisone affects the HPA system in the body. Cortisol production can be greatly impacted by long term use of prednisone. GI adverse effects can be problematic with oral prednisone which is why we often give this medication with food or milk. Hyperglycemia is a complication from the use of prednisone. I've commonly seen blood sugar spike by 50-100+ mg/dL due to this medication. Osteoporosis is a long term risk with the use of prednisone. Prednisone can also impact the benefits of vaccination. I discuss this in greater depth in the drug interactions portion of the podcast.
In this episode of the STR Data Lab, Jamie Lane, Chief Economist at AirDNA, is joined by Bram Gallagher, Director of Forecasting at AirDNA. The duo discusses several pressing topics within the short-term rental industry and broader economic indicators. They begin by reviewing March performance and early April trends, noting a mixed story influenced heavily by recent tariff announcements. Despite a challenging 2023, 2024 saw positive momentum, particularly in mountain resorts benefiting from good snowfall. However, March presented a slight decline in demand growth and occupancy rates, partly due to a calendar shift with spring break and Easter moving to April. Urban markets saw significant new listings, leading to a notable increase in supply, especially in cities like Jersey City and Newark, following New York's short-term rental regulations. Interest rates, inflation, and consumer confidence are discussed in depth. Bram notes a hesitant stance from the Fed to lower interest rates due to inflationary pressures. Employment remains strong, but consumer confidence and business sentiment have declined. The discussion also touches on the impact of exchange rates on international travel, with Americans potentially favoring domestic destinations due to a weaker dollar against the Euro. Further, summer travel pacing shows positive trends in traditional vacation rental markets but sluggish demand in urban and suburban areas. Lastly, the episode delves into price evolution, with March showing smaller increases in average daily rates (ADRs) compared to January and February, highlighting affordability concerns amid economic uncertainties. Bram concludes with a look ahead, emphasizing the importance of monitoring layoffs and wage inflation as critical indicators for the economic outlook. You don't want to miss this episode! ~~~~ Signup for AirDNA for FREE
Join Mike, Rikki, and Scott today as we answer lots of your Listener Questions! We talk about options for a stay for a large group coming down for a Disney Treasure cruise, staying a few nights prior with no theme park tickets, but ADRs at O'hana and going to Hoop Dee Doo Revue and looking for some resort options! We also talk about some great breakfast ADRs around property as well as options for friends to meet some other friends outside the theme parks for dinner later in the day who don't have theme park tickets like they do! We also talk the latest on the Test Track refurbishment too! This and much more on today's show! Please come join the BOGP Clubhouse on our Discord channel at www.beourguestpodcast.com/clubhouse! Thank you so much for your support of our podcast! Become a Patron of the show at www.Patreon.com/BeOurGuestPodcast. Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika VijayIn this episode, I will be discussing Serotonergic drugs like Psychedelics, drugs for anxiety, depression and psychosis- and their applications, ADRs, etc. I will be talking about all these in quite detail. I will also talk about Serotonin Syndrome in detail.My podcast is featured in "BEST SCIENCE PODCASTS"- Check the link here:https://podcasts.feedspot.com/india_science_podcasts/My podcast is featured in "BEST INDIAN MEDICAL PODCASTS". Check the link here:https://podcasts.feedspot.com/india_medical_podcasts/?feedid=5503395For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine."Pharmacology Further" E-Newsletter and Podcast:The links for these are at all my websites and specifically:Link for E-Newsletter: https://pharmacologyfurther.substack.com/Link for the E-Newsletter Podcast: https://www.pharmacologyfurther.comIt actually contains lot of updates about the medical sciences, drug information and my podcast updates also.You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!Please leave Review on Apple podcasts!My E-Newsletter sign up at Substack!Connect on Twitter & Instagram!My books on Amazon & Goodreads!
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika VijayIn this episode, I will be discussing Serotonergic drugs like Psychedelics, drugs for anxiety, depression and psychosis- and their applications, ADRs, etc. I will be talking about all these in quite detail. I will also talk about Serotonin Syndrome in detail.My podcast is featured in "BEST SCIENCE PODCASTS"- Check the link here:https://podcasts.feedspot.com/india_science_podcasts/My podcast is featured in "BEST INDIAN MEDICAL PODCASTS". Check the link here:https://podcasts.feedspot.com/india_medical_podcasts/?feedid=5503395For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine."Pharmacology Further" E-Newsletter and Podcast:The links for these are at all my websites and specifically:Link for E-Newsletter: https://pharmacologyfurther.substack.com/Link for the E-Newsletter Podcast: https://www.pharmacologyfurther.comIt actually contains lot of updates about the medical sciences, drug information and my podcast updates also.You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!Please leave Review on Apple podcasts!My E-Newsletter sign up at Substack!Connect on Twitter & Instagram!My books on Amazon & Goodreads!
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika VijayIn this episode, I will be discussing Triptans' clinical applications, ADRs and all about Ergot derivative use in migraine.I will be talking about all these in quite detail. Discussions like pathophysiology, serotonin signalling, drugs related and receptor related to serotonin and migraine will be adding spice to the episode.My podcast is featured in "BEST SCIENCE PODCASTS"- Check the link here:https://podcasts.feedspot.com/india_science_podcasts/My podcast is featured in "BEST INDIAN MEDICAL PODCASTS". Check the link here:https://podcasts.feedspot.com/india_medical_podcasts/?feedid=5503395For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine."Pharmacology Further" E-Newsletter and Podcast:The links for these are at all my websites and specifically:Link for E-Newsletter: https://pharmacologyfurther.substack.com/Link for the E-Newsletter Podcast: https://www.pharmacologyfurther.comIt actually contains lot of updates about the medical sciences, drug information and my podcast updates also.You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!Please leave Review on Apple podcasts!My E-Newsletter sign up at Substack!Connect on Twitter & Instagram!My books on Amazon & Goodreads!
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika VijayIn this episode, I will be discussing Triptans' clinical applications, ADRs and all about Ergot derivative use in migraine.I will be talking about all these in quite detail. Discussions like pathophysiology, serotonin signalling, drugs related and receptor related to serotonin and migraine will be adding spice to the episode.My podcast is featured in "BEST SCIENCE PODCASTS"- Check the link here:https://podcasts.feedspot.com/india_science_podcasts/My podcast is featured in "BEST INDIAN MEDICAL PODCASTS". Check the link here:https://podcasts.feedspot.com/india_medical_podcasts/?feedid=5503395For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine."Pharmacology Further" E-Newsletter and Podcast:The links for these are at all my websites and specifically:Link for E-Newsletter: https://pharmacologyfurther.substack.com/Link for the E-Newsletter Podcast: https://www.pharmacologyfurther.comIt actually contains lot of updates about the medical sciences, drug information and my podcast updates also.You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!Please leave Review on Apple podcasts!My E-Newsletter sign up at Substack!Connect on Twitter & Instagram!My books on Amazon & Goodreads!
In the latest SBC Podcast I am joined by Josh to talk about a project that we have launched in February to help punters everywhere.Bookmaker disputes are the most common complaint that we receive here at the SBC and Gambling Commission in the UK have highlighted it as a major frustration for punters too (they haven't done anything about it but that's another story!).To help, we have created a brand-new guide that can help walk you through what to do in spots where bookmakers create friction at withdrawal. You can get your FREE SBC Bookmaker Dispute Document here: https://smartbettingclub.com/bookmaker-dispute-guidance/.In this podcast we discuss the whats and whys of the guide, with some of our personal experiences and opinions intertwined into the chat. Please feel free to share the guide with anyone you feel could benefit from what is inside - it's free for everyone and despite being 'UK-centric' - many of these firms are international companies and apply similar policies in different jurisdictions.You can support the SBC Podcast by visiting our brand-new podcast sponsor, Matchbook. You can get 150 days, commission free with them via this link.(00:00) Introduction(01:31) Why Are We Here?(04:03) Just A UK Problem?(07:09) Withdrawal Woes & Loose T & Cs(13:21) Big Brother Is Watching You!(19:51) Prevention(27:34) Disputes - How To Handle Them(37:45) Showing You Know What You're Doing(39:15) ADRs - Are They Worthwhile?(42:42) Considering Court Action(47:25) Court Claims For Larger Amounts(51:20) Other Tips & Tricks(52:20) The Guide & Final Thoughts
Von den 13.000 internationalen Aktien, die an der Börse gehandelt werden können, sind viele gar nicht die Originalaktien, sondern Austauschscheine. ADRs, GDRs oder nur DRs genannt. Über diese Wertpapierart sprechen wir mit dem Spezialisten Manuel Tulezi, der für die ICF BANK an der Frankfurter Börse tätig ist. Was sind Austauschscheine, was unterscheidet sie von den Aktien, die sie vertreten. Wie sieht es mit Aktionärsrechten wie Gewinnbeteiligung und Stimmrechten aus? Gibt es Unterschiede im Handel?
Join Mike & Pam today as we answer your Listener Questions! Today we have a discussion on the similarities and differences between Castaway Cay and Lighthouse Point, as well as the similarities and differences between the newer, larger ships in the DCL fleets vs. the Classic Disney Magic and Wonder. We also discuss adding a 7th guest to an ADR coming up at Topolino's Terrace (and why this makes Mike very nervous!), registering for runDisney events, and booking Lightning Lanes on different dates. This and much more on today's show! Please come join the BOGP Clubhouse on our Discord channel at www.beourguestpodcast.com/clubhouse! Thank you so much for your support of our podcast! Become a Patron of the show at www.Patreon.com/BeOurGuestPodcast. Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
Human and veterinary pharmacovigilance (PV) share many goals, challenges and approaches. But there are also significant differences, such as the numerous animal species that veterinary PV needs to take into account. In this two-part episode of Drug Safety Matters, James Mount, Veterinary Pharmacovigilance assessor at the Swedish Medical Products Agency, and EU elected chair of the Pharmacovigilance Working Party for veterinary medicinal products, joins the show to talk about veterinary PV practice and its differences and similarities to human PV. In part 2, you will hear aboutdifferences in types of ADRs reported for animals as compared to humans,when humans are accidentally exposed to medicines for animals, and vice versa,how the many species and breeds included in veterinary PV affects the coding of ADR reports, breed-specific ADRs – what is safe for one breed of e.g. dog or pig, may not be appropriate for another, the EU Veterinary Big Data Strategy,... and much more! Links for further readingThe public portal of the European Union Veterinary Pharmacovigilance Database.One Health – an integrated approach to the well-being of people, animals and the environment.A survey of veterinary professionals in Sweden, about practices and attitudes in relation to ADR reporting.A review of adverse events in animals and children after secondary exposure to transdermal hormone-containing medicines. The EMA Big Data strategy for veterinary medicines. Data quality framework for medicines regulation | European Medicines Agency (EMA)Small Animal Veterinary Surveillance Network (SAVSNET) - University of LiverpoolVetCompass - Royal Veterinary College, RVCReflection paper on the use of artificial intelligence in the lifecycle of medicines | European Medicines Agency (EMA)Veterinary good pharmacovigilance practices (VGVP) | European Medicines Agency (EMA)Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) | European Medicines Agency (EMA) Join the conversation on social mediaFollow us on X, LinkedIn, or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we work to advance medicines safety.
Best Low-Carbon ETFs and Stocks includes reviews of two articles by financial analysts at the highly respected Carbon Credits organization. By Ron Robins, MBA Transcript & Links, Episode 146, January 24, 2025 Hello, Ron Robins here, welcome to my podcast episode 146 published January 24, 2025, titled “Best Low-Carbon ETFs and Stocks.” It's presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Now I'm having to record this podcast two days earlier than usual. But it is still filled with great, up-to-the-minute, informative articles! Also, remember that you can find a full transcript and links to content – including stock symbols and bonus material – on this episode's podcast page at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, and I don't receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal any investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief. Please go to this podcast's webpage for links to the articles and more company and stock information. ------------------------------------------------------------- Best Low-Carbon ETFs and Stocks (1) Today, I'm starting with two articles on low-carbon ETFs and stocks from analysts at carboncredits.com. The first article is titled Top 5 Carbon ETFs for Sustainable Investing in 2025. It's by Saptakee S. Here are the picks and brief quotes from the article. “1. iShares Global Clean Energy ETF (ICLN) is a part of BlackRock and a top-performing ETF… Essentially, this fund tracks an index of stocks in the global clean energy sector. One important attribute of this ETF is its strict sustainability rules. It excludes companies involved in weapons, tobacco, coal, oil sands, and Arctic drilling. (It) currently manages assets worth $5-6 billion. 2. Invesco Solar ETF (TAN) known as TAN, manages assets valued between $3–4 billion… This fund focuses on solar energy companies, such as manufacturers, installers, and technology providers… TAN is based on the MAC Global Solar Energy Index. It invests 90% of its assets in securities, American depositary receipts (ADRs), and global depositary receipts (GDRs) listed in the index… 3. First Trust Global Wind Energy ETF (FAN) known as FAN, currently manages assets worth $2–3 billion… It's prospective for those managing wind farms, producing wind power, or making wind energy equipment. However, companies must have a market cap of at least $100 million, a daily trading volume of $500,000, and a free float of 25% to join the index. 4. SPDR S&P Kensho Clean Power ETF (CNRG) currently has assets worth $1–2 billion… It is managed by State Street's Investment Solutions Group and is built for long-term growth. With its focus on innovation and the clean energy sector, this ETF is a great option for those wanting to invest in the future of renewable energy. 5. Global X Lithium & Battery Tech ETF (LIT) gives investors access to the booming electrification, lithium, and battery technology sector. Their assets have a $4–5 billion valuation… The ongoing global demand for lithium and supply constraints make this ETF a promising investment in this sector.” End quotes. ------------------------------------------------------------- Best Low-Carbon ETFs and Stocks (2) Now this is the second article on Low-Carbon investments titled Top 5 Carbon Stocks to Watch in 2025. It's by Jennifer L. and also found on carboncredits.com. “1. Brookfield Renewable Partners (BEP) is one of the world's largest publicly traded renewable energy companies. With a clear focus on clean, renewable energy, Brookfield Renewable Partners distinguishes itself from many of its competitors by operating as a pure-play renewable energy company. This means that its portfolio consists exclusively of renewable sources of power generation, unlike other companies that often combine renewable energy with fossil fuel assets. As of 2024, Brookfield Renewable Partners diversified portfolio encompasses over 35,000 megawatts of operating capacity across various renewable energy sources. This extensive array of assets spans multiple regions, including North America, South America, Europe, and Asia, underscoring Brookfield Renewable Partners commitment to global renewable energy development. For investors seeking exposure to the renewable energy sector with a preference for established companies demonstrating stable growth and reliable returns, Brookfield Renewable Partners represents a compelling option. 2. Aker Carbon Capture ASA (AKCCF) is a Norwegian company specializing in carbon capture technology. Leveraging its expertise from the Aker Group, a global leader in offshore engineering, Aker Carbon Capture has developed modular carbon capture systems that are both cost-effective and scalable… With a solid financial foundation and strategic partnerships, Aker Carbon Capture is well-positioned to expand its carbon capture solutions globally. The aim is to contribute significantly to the reduction of industrial CO₂ emissions and support the transition to a low-carbon economy. 3. LanzaTech Global, Inc. (LNZA) is a pioneering carbon recycling company that transforms waste carbon emissions into sustainable fuels and chemicals through innovative biotechnology using gas fermentation. Through this process, industrial emissions—rich in carbon monoxide and carbon dioxide—are converted into ethanol and other chemicals… The ethanol produced can serve as a building block for various products, including jet fuel, plastics, and synthetic fibers. With a solid financial foundation bolstered by recent capital raises and strategic partnerships, LanzaTech is well-positioned to expand its carbon recycling solutions globally, creating sustainable products from waste carbon. 4. Occidental Petroleum Corporation (OXY) is a major player in the oil and gas industry. However, in recent years, the company has been transforming itself into a leader in carbon management solutions. Occidental has embraced Direct Air Capture (DAC) technology, which removes CO₂ directly from the atmosphere. In partnership with Carbon Engineering, Occidental is constructing the world's largest DAC facility in Texas, a groundbreaking project that will play a significant role in achieving global emission reduction targets… Occidental's approach is an example of how traditional energy companies are evolving to embrace sustainability. By combining its existing expertise in oil extraction with innovative carbon capture methods, Occidental is paving the way for a future where fossil fuel extraction can coexist with carbon reduction technologies. 5. Equinor ASA (EQNR) formerly known as Statoil, is a Norwegian energy giant that has diversified its portfolio to include renewable energy sources like wind power. It has also been at the forefront of carbon capture, utilization, and storage (CCUS) technologies for over 25 years… Equinor is a key player in the Northern Lights project, a pioneering initiative in Norway aimed at developing a large-scale carbon capture and storage infrastructure… Equinor has decades of experience in offshore oil and gas exploration. Its deep-rooted knowledge of energy infrastructure is key to its success in developing large-scale carbon capture and storage solutions. With the potential to store the equivalent of 1,000 years of Norwegian CO₂ emissions beneath the seabed, Equinor's initiatives are pivotal in supporting global climate goals.” End quotes. ------------------------------------------------------------- Best Low-Carbon ETFs and Stocks (3) Still, on the theme of energy-related investments is this article titled 3 Renewable Energy Stocks to Buy in 2025 and Hold for Decades. It's by James Brumley and found on fool.com. Here is some of what Mr. Brumley says about his picks. “1. Cameco (NYSE: CCJ) one of the planet's top suppliers of uranium, with access to plenty of high-grade reserves. Its two chief mining operations in Saskatchewan, Canada, are currently jointly capable of producing a total of 43 million pounds of high-grade uranium per year, but both could support more output at only marginally more cost… Do prepare for continued volatility from Cameco stock that reflects the continued volatility of uranium prices -- although maybe not quite as much as you might expect. Confidence in nuclear power as a clean source of electricity is slowly but surely improving, leveling out these swings. 2. Brookfield Renewable (BEPC -2.65%) (BEP -1.29%). (Yes, a second recommendation in this podcast.) If you feel confident that renewable energy as an industry is investment-worthy but you don't know where to start, consider a stake in Brookfield Renewable Corp. With it, you'll own a little of everything the business encompasses… There is one detail worth pointing out there. That is, this is not Brookfield Asset Management (BAM.TO), Brookfield Corporation (BN), or Brookfield Wealth Solutions (BNT). Although all of these companies are related, Brookfield Renewable is the only one with direct exposure to the alternative energy market. The others are simply involved in the management and marketing of Brookfield Renewable. 3. First Solar (NASDAQ: FSLR) First Solar stock is down nearly 40% from its June peak largely on concerns that President-elect Donald Trump isn't as supportive of solar power as his predecessor was. And maybe he isn't. The solar tax credits that boosted the business under President Joe Biden's watch are anything but guaranteed to last through Trump's tenure… The irony is that the analyst community is still calling for strong growth from First Solar regardless of who's occupying the White House. Last year's projected top-line growth of 29% is expected to be followed by 32% growth this year, followed by 21% revenue growth next year. Even producing half of that anticipated growth should shake this stock out of its current funk and rekindle a long-term advance.” End quotes. ------------------------------------------------------------- Best Low-Carbon ETFs and Stocks (4) And, yes, another analyst article on the renewable energy theme — but with a very different angle. It's titled 2 Renewable Energy Stocks to Buy in 2025 and Hold for Decades by Leo Sun on aol.com. It was originally published on fool.com. “1. NuScale Power (NYSE: SMR) produces the only small modular reactors (SMRs) that have been certified with a Standard Design Approval (SDA) from the U.S. Nuclear Regulatory Commission (NRC). Its SMRs can be installed in vessels that are just 9 feet (2.7m) wide and 65 feet (20m) tall -- which makes them much easier to deploy than larger nuclear reactors. NuScale's modular designs are prefabricated, delivered, and assembled on-site. That approach reduces the costs and construction time of a working nuclear reactor. Its current reactor clusters are certified for up to 55 megawatts of electricity… NuScale's stock has already surged nearly 650% over the past 12 months in anticipation of that approval, but it still trades more than 20% below its all-time high from last November. Analysts only expect its revenue to rise 4% to $24 million in 2024. 2. CleanSpark (NASDAQ: CLSK) develops modular microgrids for wind, solar, and other renewable energy sources. These microgrids can be deployed as stand-alone systems or plugged into existing energy grids, and they're used to funnel energy into storage systems, backup generators, and load management solutions. CleanSpark initially developed these green energy systems for other companies, but it evolved into a Bitcoin miner upon acquiring ATL Data Centers in May 2021. It upgraded ATL's mining facilities with its technology to boost their efficiency and demonstrate that it was possible to mine Bitcoins with low-carbon energy… From fiscal 2024 to fiscal 2027, analysts expect its revenue and adjusted EBITDA to grow at a CAGR of 36% and 22%... That makes it a great long-term play if you expect Bitcoin's price to keep climbing and the renewable energy market to keep expanding.” End quotes. ------------------------------------------------------------- Additional article not covered due to time constraints 1. Title: Start-up Bountiful Financial Launches Stock Indices Based on Religious Teachings & Believers' Real-World Experiences. Media release. ------------------------------------------------------------- Ending Comment These are my top news stories with their stock and fund tips for this podcast “Best Low-Carbon ETFs and Stocks.” Please click the like and subscribe buttons wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these terribly troubled times! Contact me if you have any questions. Thank you for listening. I'll talk to you next February 7th. Bye for now. © 2025 Ron Robins, Investing for the Soul
This interview was recorded for GOTO Unscripted.https://gotopia.techRead the full transcription of this interview hereSam Newman - Microservices Expert & Author of "Monolith to Microservices" & "Building Resilient Distributed Systems"Julian Wood - Serverless Developer Advocate at AWSRESOURCESSamhttps://twitter.com/samnewmanhttps://hachyderm.io/@samnewmanhttps://www.linkedin.com/in/samnewmanhttp://samnewman.iohttp://samnewman.io/bloghttps://github.com/snewmanJulianhttps://bsky.app/profile/julianwood.comhttps://twitter.com/julian_woodhttps://www.linkedin.com/in/julianrwoodDESCRIPTIONJulian Wood and Sam Newman delve into the complexities of software architecture, focusing on critical concepts such as microservices, asynchronous communication, and the importance of architectural decision-making.Sam emphasizes the need for clear definitions in computing, particularly around terms like asynchronicity, advocating for an understanding of communication styles—event-driven versus request-response—as pivotal for effective system design. They discuss the value of architectural decision records (ADRs) as tools for fostering collaboration and documenting trade-offs in decision-making.Additionally, the conversation highlights the evolving role of AI in software development, stressing that while AI can assist in understanding and maintaining existing codebases, the human element of critical thinking remains essential in navigating the complexities of modern software systems.RECOMMENDED BOOKSSam Newman • Building Resilient Distributed Systems • https://www.oreilly.com/library/view/building-resilient-distributed/9781098163532Sam Newman • Monolith to Microservices • https://amzn.to/2Nml96ESam Newman • Building Microservices • https://amzn.to/3dMPbOsRonnie Mitra & Irakli Nadareishvili • Microservices: Up and Running• https://amzn.to/3c4HmmLMitra, Nadareishvili, McLarty & Amundsen • Microservice Architecture • https://amzn.to/3fVNAb0BlueskyTwitterInstagramLinkedInFacebookCHANNEL MEMBERSHIP BONUSJoin this channel to get early access to videos & other perks:https://www.youtube.com/channel/UCs_tLP3AiwYKwdUHpltJPuA/joinLooking for a unique learning experience?Attend the next GOTO conference near you! Get your ticket: gotopia.techSUBSCRIBE TO OUR YOUTUBE CHANNEL - new videos posted daily!
Welcome back to Short-Term Rental Riches! I'm excited to be home in Medellin after visiting California, where I got to check in on my first short-term rental properties from 2015. This episode is all about the big takeaways from 2024 and what to expect in 2025. If you've been hosting Airbnb guests or managing short-term rentals, you know that market trends change fast—and understanding STR market trends for 2025 can be your key to maintaining high occupancy and revenue. This year, I've seen a significant drop in new STR supply, but demand has remained strong, creating a huge opportunity for hosts who are leveraging the right strategies. I'll cover the most important trends, including how AI is reshaping how guests search for properties and why Google Vacation Rentals could be a game-changer for direct bookings. If you're using tools like Price Labs or considering listing on Google to avoid commission fees, this is your guide to staying competitive. Whether you're focused on increasing your Airbnb revenue or refining your guest experience to earn more five-star reviews, this episode is packed with practical advice. Let's dive in and set you up for success in 2025! If you're looking to increase your Airbnb revenue and optimize your STR listings, this episode is packed with actionable tips! In this episode, you'll learn: Occupancy Trends & Supply Slowdown: STR supply is stabilizing or decreasing in some markets, giving established listings an edge to increase bookings. Average Daily Rate (ADR) Adjustments: Nationwide, ADRs have dipped slightly, making dynamic pricing tools like Price Labs essential for maximizing your revenue. AI's Impact on Search: Guests are using AI-based searches to find highly specific STRs. Properties that align with personalized searches will see increased visibility. Google Vacation Rentals: Google's no-commission listing option is a game-changer for direct bookings. Partnering with platforms like Hostaway makes integration seamless. Long-Term Strategy with Direct Bookings: A direct booking website can reduce your reliance on platforms like Airbnb and VRBO, especially as competition grows. Thanks for tuning into Short-Term Rental Riches! With the 2025 market shaping up, staying informed and proactive can help you outpace the competition. Whether it's leveraging AI to boost your listing visibility, optimizing your pricing strategy, or listing on Google Vacation Rentals, there's never been a better time to strengthen your short-term rental business. Need help managing your short-term rental and you don't want to go it alone? Shoot us a message here and we'll see if we can help. Drop your thoughts or questions in the comments and let me know what trends you're seeing in your market. Don't forget to like, and subscribe for updates. Here's to crushing your 2025 STR goals—see you in the next episode! You can find all of our links here including our website, recommended resources, upcoming live event, short-term rental playbook, Instagram, and more!
Mike, Scott, and Rikki are here today answering your awesome Listener Questions! Today, we discuss options to get your coffee before heading out to the corrals at WDW Marathon Weekend, ADRs for a group of 8 headed down in February where their ADR "window" is already open and they can still find decent availability, nice "brunch" options for a Bachelorette Party, taking advantage of the "Free" water park day for on-site guests in 2025 and much more! Please come join the BOGP Clubhouse on our Discord channel at www.beourguestpodcast.com/clubhouse! Thank you so much for your support of our podcast! Become a Patron of the show at www.Patreon.com/BeOurGuestPodcast. Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
Happy New Year! This special episode - our annual reflection on the last 12 months and a look at where we are going in 2025 - features none other than David Angotti. David's been in the short-term rental world for years and has done it all - co-founding tech startups, building a successful property management company in the Smoky Mountains, and now serving as Chief Evangelist at Guesty. He's also an incredible storyteller and someone who just gets the ins and outs of this business like few others. Having him on the show is always a treat, and I couldn't think of a better way to set the tone for the year ahead. In this episode, we take a look back at 2024 - what worked, what didn't, and the lessons we can carry forward. From evolving guest expectations to AI tools that can transform your business, David shares his perspective on what's next for the vacation rental industry and how you can thrive in 2025. What You'll Discover: Evolving Guest Expectations: Insights into how guest expectations are shifting and what property managers can do to meet these rising standards. Technological Advancements: Discussion on the critical role of technology in shaping the operations and efficiency of vacation rental businesses. Regulatory Challenges: Overview of the regulatory landscape in 2024 and how it might affect the industry moving forward. Market Dynamics: Analysis of market trends, including occupancy rates and average daily rates (ADRs), and their implications for property managers. Actionable Strategies for 2025: David shares practical strategies to help property managers and hosts thrive in the coming year, considering the ongoing industry transformations. You Will Learn: Adaptation to Market Changes: How to remain flexible and adaptable in a rapidly evolving industry to maintain competitiveness. Leveraging Technology: Ways to integrate and leverage new technologies to enhance operational efficiency and guest satisfaction. Navigating Regulations: Strategies to effectively manage and adapt to new and existing regulations within the vacation rental sector. Understanding and Setting Guest Expectations: Tips on managing guest expectations to ensure satisfaction and repeat business. Forecasting and Planning: How to use market data and trends from 2024 to better prepare for the opportunities and challenges of 2025. Connect with David Angotti: Listeners can connect with David through his LinkedIn profile or explore further insights and resources at Guesty's website. Revolutionize Your Employee Onboarding with THRIVE Essentials: Faster Training, Stronger Teams, Better Results! Discover how THRIVE Essentials accelerates onboarding for new property management staff, boosting performance and reducing turnover. >> THRIVE Essentials Are you listening to this podcast on the move? Get to the show notes here: https://www.vacationrentalformula.com/VRS592
In this compilation program, Justin Klein and Luke Guerrero field a variety of finance and investment questions from callers across the United States and around the world.Today's Stocks & Topics: Finance Books, ADRs vs. Buying Foreign Stocks, Buying in Credit Card Companies, KPP Management of ETFs, Asset Allocation, Annuities, Investing in Other Markets, Taking Profits, Insider Buying, Transferring 401k to a Roth 401k, I-R-A Money, Portfolio Diversification, Balancing a Portfolio, What's Wrong With Edward Jones, 401 and 427 Plans, Dual Direction Funds, Expense Ratios.Our Sponsors:* Check out Indochino: https://indochino.com/INVEST* Check out Trust & Will: https://trustandwill.com/INVESTAdvertising Inquiries: https://redcircle.com/brands
Participe do Evento Seleção 10x: https://lvnt.app/z986ol 02/12 - Bolsa -0,34%, Dólar R$ 6,065, PETZ3 +3% e AZUL4 -7% Por que a Bolsa performou assim? 1º. O Ibovespa futuro abriu em leve alta de 0,10% com investidores animados com minério e petróleo em alta bem como ADRs de Vale e Petrobras subindo um pouco, porém a combinação de três fatores fizeram a bolsa perder força e ir para o campo levemente negativo. O primeiro motivo foi as projeções do Focus com inflação mais alta em 2025, de 4,34% para 4,40%, com Selic de 12,63% para dezembro de 2025 versus 12,25% na semana passada e PIB de apenas 1,95% no próximo ano versus 3,20% em 2024. O segundo motivo foi a alta do dólar logo de manhã para até R$ 5,08, fechando a R$ 5,065, alta de 1,13% no dia, influenciado pelo moeda norte-americana que avançou 0,60% versus moedas fortes (euro, iene, libra esterlina, dólar canadense e mais duas moedas) em função dos juros longos dos EUA que subiram de 4,17% para 4,19% a.a. junto com a incerteza quanto a política comercial americana depois que Trump 2, tomar posse em 20/1/25. O terceiro motivo foi mais um dia de altas nas taxas de juros longo prazo no Brasil reflexo do dólar mais alto que tende a pressionar a inflação porque boa parte dos produtos brasileiros – de milho e soja a aço e celulose passando por derivados de petróleo – costuma subir nas semanas e meses seguintes a uma alta expressiva do dólar norte-americano, como foi agora com a moeda indo de R$ 5,40, em setembro, para mais de R$ 6,00 hoje – uma alta de 11% em três meses. O quarto motivo foi a ameaça de Trump de colocar um tarifa de importação de 100% aos produtos dos países do BRICS (Brasil, Rússia, Índia, China, África do Sul) caso eles parem de negociar em dólares seus respectivos produtos para adotar um nova moeda ou apoiar outra já existente. 2º. Na B3, 7 ações subiram entre as 15 ações mais negociadas com destaques para: PETR4 1,1% R$ 39,33, ABEV3 3,8% R$ 13,22, VALE3 0,7% R$ 59,18, B3SA3 1,5% R$ 9,40, prio3 0,4% R$ 40,31, ELET3 0,2% R$ 34,42. 3º. Já 8 ações caíram entre as 15 mais negociadas com destaques para: ITUB -0,9% R$ 32,28, BBDC4 -2,45 R$ 12,33, RENT3 -2,2% R$ 36,73, BBAS3 -0,8% R$ 24,56, ITSA4 R$ -1,5%. 4º. O preço do petróleo não aguentou a alta de 1% de manhã e fechou estável em US$ 71,8 por barril dentro do limite da volatilidade diária de -/+2%, e esse nível de preço preocupa porque se aproxima dos US$ 70 que é um suporte muito importante. O motivo do preço de US$ 86, em julho, para US$ 71,8 hoje é o excesso de oferta de petróleo diariamente pelos países da Opep+, responsável, por 35% da produção mundial, e países como EUA, Canadá, Brasil e Guianas que estão produzindo mais e exportando. A demanda mais fraca da China também explica a queda do preço do petróleo. Porém, só há uma solução de curto prazo para o preço do petróleo recuperar e voltar para US$ 75-US$ 80: os países da Opep+ concordarem com uma redução de produção na próxima reunião do grupo que ocorrerá em 5 de dezembro até 8. Se não vier uma redução significativa o preço do petróleo poderá ir a US$ 70. Se for a US$ 70, todos os países e cias. exportadoras de petróleo perderão e as ações das petrolíferas cairão.
Mike, Scott, and Rikki are here today answering your awesome Listener Questions! Today, we discuss tips for traveling with toddlers, but also letting the adults have some fun during the trip as well! Also, we give some thoughts on a splurge for our listener who is overcoming cancer and wants to celebrate this incredible milestone! (We are SO PROUD OF YOU!) We also give ideas for ADRs for large groups, activities around Port Canaveral, and much more! Please come join the BOGP Clubhouse on our Discord channel at www.beourguestpodcast.com/clubhouse! Thank you so much for your support of our podcast! Become a Patron of the show at www.Patreon.com/BeOurGuestPodcast. Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
Nach der Freude über das klare Wahlergebnis ist die Rally an den US-Börsen zumindest vorerst beendet. Zu den entscheidenden Bremsfaktoren gehören die neuen Inflationsdaten und das Comeback des Begriffs Trumpflation. Die von Donald Trump angekündigten wirtschaftspolitischen Maßnahmen könnten zu einem neuen Preisschub führen. Wie berechtigt ist die Sorge?Anschließend rückt mit Spotify ein Einzelwert ins Zentrum. Der Musikstreaming-Dienst hat die neue Bilanz präsentiert und qualifiziert sich damit für den Investment-Check. Im Anschluss geht es nach Deutschland. Das Dax-Update führt zum Chemiekonzern Bayer, dessen Aktie nach erneut schwachen Zahlen weiter abrutschte. Minus 40 Prozent sind es seit Jahresbeginn. Dennoch oder genau deshalb gehört die Aktie auf die Watchlist. In der Community-Corner wird diesmal die Frage beantwortet, was ADRs von Aktien unterscheidet und was interessanter für Anleger ist. ID:{55RxP9piOg6Cmk40Je1Fp7}
Entre agora para o grupo exclusivo da maior Black friday da história da Levante: https://sendflow.pro/i/sc9haBSIFKFERS... 11/11 - Bolsa estável, Dólar R$ 5,77, COGN3 +8% e CSNA3 -3% Olá, seja bem-vindo a mais um Fechamento de Mercado, comigo Flávio Conde e Ricardo, hoje é 2ª. feira, 11 de novembro, e o programa é dedicado ao Thiago, Emerson, Dr. Nelson e Wilker, clientes do Sala VIP, que fizemos reuniões mensais hoje. O Ibovespa fechou estável aos 127.837 pontos, depois de passar boa parte do dia no negativo, com volume bom de R$ 20 bi, R$ 2 bi acima da média de R$ 20 bi das segundas. Por que a Bolsa performou assim? 1º. A bolsa já abriu caindo chegando na mínima de 127,3 mil, às 10h50, e se recuperando a tarde para fechar estável a 137.837 pontos. Os mercados brasileiros já abriram caindo com investidores na defensiva perante as incertezas quanto ao pacote de corte de gastos, bem com petróleo caindo -2,5% e minério -2,8% e colocando os ADRs de Petro e Vale no negativo antes da abertura dos mercados e dólar a R$ 5,81. Entretanto, ao longo do dia o dólar foi recuando e fechou até caindo, um centavo, a R$ 5,77, e ações se recuperando perto da estabilidade. 2º. Na B3, 9 ações subiram entre as 15 ações mais negociadas com destaques para: Petrobras, Localiza, Embraer e PRIO. 3º. Já 6 ações caíram entre as mais negociadas com destaques para: B3, Bradesco, Magalu e Renner 4º. O preço do petróleo apresentou forte queda de -2,5%, a US$ 72,0 de US$ 74,8, na sexta, acima do limite da volatilidade diária de -/+2%, em função da fraqueza da demanda, principalmente, da China 5º. O minério de ferro caiu bem, -2,8% a US$ 105,8 de US$ 108,8, na sexta, e acima do limite da volatilidade diária de -/+2%, devido ao ceticismo dos traders de que o pacote chinês para as principais províncias do país surta o efeito desejado de maior ritmo da atividade econômica. 6º. As bolsas americanas subiram em níveis diferentes, 0,1% Nasdaq e 0,7% Dow, junto com o dólar que se valorizou 0,45% frente moedas fortes e os juros dos títulos de 10-anos estáveis a 4,30% a.a. 7º. O dólar à vista recuou 1 centavo para R$ 5,77 de R$ 5,78, na sexta, dentro da volatilidade média de -2/+2 centavos por dia, em função da forte entrada de recursos de exportações hoje. 8º. O saldo de investimentos estrangeiros no mercado secundário da Bovespa, de ações já em circulação, ficou positivo em R$ 119,15 milhões na quinta-feira, 7 de novembro, conforme dados da B3. No acumulado do mês, os estrangeiros trouxeram para o mercado secundário da Bovespa R$ 564,3 milhões. No ano, o saldo de estrangeiros está negativo em R$ 22,287 bilhões, com R$ 30,197 bilhões em vendas líquidas o mercado secundário e compras de R$ 7,910 bilhões em ofertas públicas. MAIORES ALTAS COGN3 +9.56% R$ 1,49 YDUQ3 +5.87% R$ 10,83 RECV3 +4.71% R$ 18,46 ALPA4 +4.13% R$ 6,80 TIMS3 +4.09% R$ 16,56 MAIORES BAIXAS CSNA3 -3.91% R$ 11,29 VALE3 -3.27% R$ 58,65 TOTS3 -2.79% R$ 30,00 USIM5 -2.56% R$ 6,09 EGIE3 -2.16% R$ 39,40 Conheça a Levante Investimentos: Conheça nossas *Séries de Investimentos*: https://lvnt.app/4q3u3b Acompanhe nosso Instagram: / levante.investimentos Fique ligado nas principais notícas do mercado no nosso canal no Telegram: https://lvnt.app/zuntm0
According to a Harvard Business Review report, about 70% of change initiatives fail. So how can enablement help sales teams navigate large-scale transformations and come out stronger on the other side of change? Shawnna Sumaoang: Hi, and welcome to the Win-Win Podcast. I am your host, Shawnna Sumaoang. Join us as we dive into changing trends in the workplace and how to navigate them successfully. Here to discuss this topic is Jenna Siegel, the director of revenue enablement at InMoment. Thank you for joining us, Jenna. I would love for you to tell us about yourself, your background, and your role. Jenna Siegel: Thank you so much for having me. I’m excited to be here. I made a large shift to land myself into enablement. So I came actually from an academia background, teaching at the University of Illinois Chicago, while I was working through some postgraduate work, and I quickly realized that academia wasn’t a place that I wanted to land for the long term. Which left me with this really kind of humbling experience of what do I want to do with my life. And I think like many people in enablement, I landed myself in sales. I was in various go-to-market roles, whether that be service, sales, or customer success, and I really quickly got frustrated with like, the lack of resources and education in the corporate space. And of course, as someone who came from an education and academia background, I was a constant advocate for we need resources to get everyone to speak the same language, to get everyone to understand the same processes. So after having worked in go-to-market roles for several years, I landed a role within enablement and I’ve been there ever since for about six years now. SS: Jenna, we’re really excited to have you here on the podcast. So thank you so much for joining us. I know your team recently went through an acquisition, which can often bring significant change for sales teams. What best practices did you implement to help your teams effectively navigate through this transition? JS: Absolutely. So acquisitions are so tricky to navigate and I really feel like they’re fear-inducing for everyone involved. So with my team, I was leading revenue enablement at a company called ReviewTrackers that was acquired by my current company called InMoment. So ReviewTrackers was a really small organization with a very small enablement org. InMoment was actually a much larger organization without any true dedicated revenue enablement. So for us, it was so easy to step into this expanded role of leading enablement across the entire organization with truly preconceived notions of what we thought would drive success, mainly because we knew what drove success at our small little scrappy company called ReviewTrackers. So the biggest challenge for me and for my team post the acquisition was really just to be curious. Right. We constantly are preaching this to our sales reps throughout the discovery phase. Be curious, ask a lot of questions, and really learn about them and their business. And I think we often forget to do that in enablement. We come in and we’re like, I know what drove success. I know that doing this sales methodology is going to work because look at the success it drove for my prior business. So we really had to adopt the same methodology in our transition. And this didn’t just involve meeting with the stakeholders and with senior leadership and presenting our expertise and our plans and getting their feedback, but I think the most important thing that we did was really step into meeting with the frontline folks, those that are executing on the role day to day and really learn about what are their challenges, what are their enablement desires, what do they wish they had, but Had never had because they didn’t have a revenue enablement dedicated role. So it was a new function to in the moment and we stepped in and I think it was split. Some people thought, Oh gosh, these people are going to come in and they’re going to make our lives miserable and they’re going to implement all these trainings and we’re, it’s going to pull us off the field. You know, our biggest strategy in the acquisition was driving trust and confidence across our teams before we ever were able to present a plan. SS: Well, it sounds like you guys did a phenomenal job really driving that trust and confidence across your teams. I know unifying the go-to-market teams is essential during these types of transitions. What challenges have you encountered in aligning your go-to-market teams and how did you overcome some of these challenges? JS: Yeah, absolutely. So I think the biggest thing is we weren’t just unifying teams, we were unifying regions. So we had three separate regions that were functioning pretty independently from each other, as well as teams, whether that be sales, success, ADRs, or our account management team that were also functioning independently from one another. And one of the first things that we identified was that there was a vast amount of technology and go-to-market processes that differed across the org, especially because of the number of mergers and acquisitions that they had gone through even prior to acquiring review trackers. And I strongly believe that these fragmented technologies and processes Also aid in creating a fragmented go-to-market organization. So I’m so grateful that I sit under a really brilliant revenue operations team that I could partner with and they could partner with enablement. So we could really understand how the technologies and processes were being used and where there was room for optimization. This was really our first step in trying to figure out how we were going to unify the teams and how we were going to get everyone working. Together and in the same direction. Don’t get me wrong. All these teams were doing really brilliant work, but it was very fragmented in nature. So in doing that, we explored how can we string together the processes and the technologies to drive adoption. So for example, we’re a MEDIC shop. Post acquisition, we implemented MEDIC methodology. And I think it’s really common to introduce selling methodologies and send everyone on their merry way and just hope that it works. You know, we can implement it for sales, we can implement it for success, we can even implement it for our account management team, and I just really hope that they put it into practice. But we had the really unique opportunity to rework the systems and the processes alongside introducing some of these new methodologies. So we were able to layer in, here’s the new methodology, let’s practice it. Let’s get it, you know, we know it’s not new to the go-to market organization. Here’s how also your technology is going to hold you accountable. So this kind of set the groundwork for how we implemented our CRM system. How we set up sales stages with exit criteria, how we deploy information through the LMS system, and it can be role-specific, but the same line of thinking to all these different go-to-market organizations. How we set up Highspot, and how Highspot is organized for all of our sales reps to use, and our go-to-market orgs to use. That was our biggest thing to tackle when we thought about how we were going to unify the teams. SS: Mm. Particularly in a merger acquisition, I know sometimes employees can feel uneasy as team structures and roles and dynamics evolve. What’s your best advice on motivating teams and reps in particular to really ease them into the process of change? JS: Yeah, I think it all goes back to communication, right? We know it’s essential to get leadership alignment first. That’s number one. If leaders are aligned and bought into the changes and brought into the processes to help define the processes, we know it’s going to trickle down to their teams. But also, we wanted our frontline people to have a voice in these changes. Silos, like especially for InMoment, we’ve seen this happen, can only bring about further anxiety and defiance and actually adopting the process and burnout employees. So we created these group of tiger teams, where we brought together leaders and individual contributors, and into these teams to help us define the processes, and poke holes through our processes. And that trickled down to the greater team because they were bought in. They could be, you know, the leaders of their team. They can advocate for these processes and these systems. And that’s where we see the most amount of success and hoping that people aren’t anxious or hoping that people can process these changes. SS: Yeah, I think buy-in is absolutely critical. From your perspective, what is maybe the strategic advantage of an enablement platform when navigating change like this? JS: Yeah, that’s a great question. And I love enablement platforms. I’m a huge believer that even the smallest go-to-market org and the smallest enablement team, it’s very hard to be effective without having a platform in place. I like to split this out into two pillars why we think enablement platforms are important or how we really use it to our advantage. One is how we deploy enablement. So how we even go about deploying enablement? The second is how we track the efficacy of the changes. And the efficacy of the enablement that we’re putting out into the field. So, regarding how we deploy enablement. Our enablement org, here at InMoment, although it has grown since the acquisition, is very small and very scrappy. And we as a small team, need to be able to scale. And when I hear people say scale, my first thought is always, Oh gosh, everything’s just going to be LMS courses. Nothing’s going to be live. We’re not going to have hands-on training. And I don’t believe that to be the case. I don’t think that scaling for our team means abandoning live training or completely avoiding the face-to-face aspect of enablement. I think it’s actually quite important in this kind of blended learning environment post-COVID and post-remote teams. Deploying enablement for us means What is going to happen after we have run the initial enablement? I quote this study to like nausea with my team that 30 days post enablement, 70 percent of the content is forgotten if we don’t do any sort of follow-up. So we really like to use our systems to give those reminders, to make the content continuously reappear post enablement. So maybe it’s using Highspot to actually send content newsletters. We deployed enablement. We know these are the pieces of content that really coincide with the enablement. We send monthly enablement newsletters actually using Highspot digital rooms, which people love so that it’s, the content stays front and center. Or maybe it’s deploying an activity in our LMS system. Hey, we ran this enablement session. Here’s this quick activity or challenge that we want you to engage in. Or also maybe it’s gamifying it through our systems to make learning a little bit more fun. We recently did Highspot scavenger hunts post-enablement. We launched a new product line. We had what we call expertise exchanges where we really shared best practices amongst the team. And part of that was a Highspot scavenger hunt of like, who can find the most relevant stats related to this product and related to the value of the product and share it with the larger team. People loved it, right? It’s different. It’s not your typical sit in hour-long live sessions where we know that. 15 minutes in we’re losing people to their email and their slack or it’s not, you know, all of a sudden we’re opening up a breakout room on Zoom and we see the attendance drop 50 percent because people just don’t maybe have anxiety around that which is also understandable, but we also need to combat. So this way of gamifying it through our systems and through our enablement platforms is really important. So that’s our first pillar. Our second pillar is how can we use our enablement systems. To measure the efficacy of our efforts. We deploy surveys. I didn’t mention this yet, but Amoment is a customer experience technology platform. We’re really big on how can we understand our customer’s experience. And here in enablement, we think our customers are all the internal folks that are on the receiving end. Surveys give us really great feedback. But they only tell a portion of the story. We can get survey feedback that’s like, everything was amazing. We love this enablement session. It was fun. I learned a lot. And then a month down the road, the data is telling us a very different story. And we really try to take a holistic approach to how we understand data. So if we run an enablement session on a product launch, anytime we run a larger initiative, my enablement team, we measure various data points to really understand where it is that we need to go next. We can look at the lagging indicators, that’s like financials and deal velocity and all of that. But I think a lot of the really good information and the juicy information lives within our enablement platforms. You know, we include attendance and completion data point. There’s quite a bit that goes into the data that we’re looking at. Conversational intelligence data, how they’re actually speaking about it in our field, but enablement metrics like Highspot metrics are really important to us. Perhaps it’s that we’ve deployed this enablement. We’re seeing a huge uptick in how they’re using the content. And then the next month, it’s not unique to InMoment. We see a huge dip down and all of a sudden no one’s using it. Well, that tells us we need to resurface this in some way, shape, or form. We need to figure out how we’re going to get people talking about this again. So it really is our signal for where do we need to re-engage and where do we need to re-evaluate our strategy. SS: I love hearing that. Shifting gears a little bit, content governance has always been a big focus for you this year with 58 percent of InMoment’s content now well governed. Congratulations. How have you been able to optimize governance and what impact has this had on your team as they navigate change? JS: Yeah, I strongly feel that we had a Bigger mountain than usual to tackle when it comes to Highspot, um, particularly because my team, again, there was an absence of a revenue enablement team at InMoment for a long time, and my team acquired Highspot, and it was a tool that was launched out to the masses without any real strategy around how it was going to be maintained. So when we acquired Highspot as a team, we had a lot to tackle. One is that there was a lot of outdated content on there. I think I found content back from 2009. Which is problematic and also just unnecessary because Highspot provides the governance tools that you would need to make sure that content is refreshed. So when we had initial conversations with our go-to market team, when the acquisition happened, I said, how are you all using Highspot? The number one answer is, Oh, we don’t look in there. There’s too much outdated information. So my team started by doing a content audit. We pulled a list of all of the content that lived within Highspot, with how many views it had. We really used the data in Highspot, how many views it had, when it was last viewed, when it was last updated, when it was originally uploaded. Unfortunately, nothing had feedback owners listed on it. So we really didn’t even know who owned the content outside of original authors or whoever uploaded it originally. So we, as an enablement org, had our product marketing teams and our marketing teams go through an exercise of marking content as. It’s outdated, remove it. It’s still relevant content, but needs updating or it’s good to go and keep it as it is. In doing that, we got our content down to, I want to say about 400 to 500 pieces of content from thousands and thousands of pieces of content, which was really big. Our next step was actually working with our go-to-market teams and creating a tiger team to figure out how do we want this organized in the system. People did not know the searching functionality well enough to be able to find the information they needed. And there were no logical spots set up in the system where they could just click in and say, Oh yeah, I’m looking for a pitch doc, so I’m going to click here, or I’m looking for a blog or a gated asset, I’m going to click here. So we worked with the various different go-to-market teams, customer success, sales, ADRs, to figure out a unified way of organizing the content within a system with the relevant filters. We know our ADRs want to filter by buyer persona. That’s how they’re going to market. And that’s how they’re prospecting. But we know that our customer success folks might not want to be only filtering by buyer persona. So we created what we think are very logical spots with the appropriate filters for the appropriate teams. And then I think the most important piece of this is that every single piece of content is required to have a content owner, a feedback owner so that people know if there is an issue with the content, it’s not a giant hole in the system where you’re just stuck with this outdated pieces of content. You have someone that you can go directly to and say, hey, this isn’t up to speed. This isn’t landing in the form. Or this has a customer who’s no longer a customer and therefore we need to take it out. That was a big piece of the puzzle as well as putting expiration dates on everything. So everything has a six-month expiration date at the six-month period. The feedback owners can review the content, mark it as still applicable, or say this needs to be removed off the system to make sure that we never get into the state that we had before. And also just a big shout-out to Highspot on that one. That was a massive undertaking and a huge project which the Highspot team helped us out on a weekend when we took the system down. They were just Malcolm, our customer success rep. He was really there to help provide us with industry best practices. I don’t think we could have done it alone and in a silo. SS: Well, I love hearing about project wins like that. In a recent webinar, you actually mentioned that your team holds monthly expertise exchanges to promote peer learning. Could you share more about this practice and how you foster a culture of ongoing learning? JS: Yeah, our expertise exchanges were created because when we stepped into the role, there was a lot of silo work going on, and we knew that enablement was never going to be effective if we did a one-and-done approach. So we created a series of expertise exchanges. We’re on a monthly cadence. We get together the various teams and we really take a look at, well, what enablement did we run this month? What was our focus? And it leaks over month to month. For example, if we’re running product training, And then we’re also running a methodology. We try and blend the two together to really make it a holistic training that the enablement efforts aren’t even siloed within itself. Every month we look at what enablement we run? What data were we trying to influence? And we figure out a theme for our expertise exchanges. So, for example, one month that theme might be a product line, right, reputation management in the field. We assign them through our LMS some pre work to do prior to these expertise exchanges so everyone comes prepared. That usually is, for example, uploading a prospecting email that you sent and then post the enablement session or providing a pitch deck or a recording of a call. We try to make it things that they’re already doing. So it’s not seen as, Oh gosh, I have to go do a mock demo or I have to create a fake pitch deck. We want it to be things that they’re actually doing within the field and it shouldn’t be a lift for them. And it’s also not a lift for enablement. It’s an easy one for enablement. Enablement reviews. Those we come together as a go-to market org. And we just call upon people. Hey, I know you all have been putting this into practice, would love to hear where you’re seeing wins, where you’re not seeing wins, and really just share amongst each other. People are very eager to share their wins, which is great. So very rarely do we have to call upon people, but we also have the submissions in advance so we can take a look at them. And if we have that moment of like no one wanting to share, call out their wins for them, right? Like, hey, I saw Caroline, that you worked on this email that actually. Our outreach data shows got 40 percent reply rate to, can you talk about your email? It’s a really great way to get people to see how they’re actually putting the enablement strategy into practice in the actual field. And also we just create a library for them in Highspot as well of like, here’s the examples of when so you can easily find them and go off and do the same. If someone else is seeing success, you should absolutely adopt that and you should absolutely put it into practice yourself. SS: I think that’s fantastic advice that our entire audience can maybe even take and apply in their organizations. As you’ve expanded and evolved your enablement strategy, what key metrics would you recommend tracking to effectively drive change? JS: Yeah, absolutely. I’m sure everyone preaches this, but I really do sit under the most brilliant revenue operations team and most brilliant revenue operations organization, which is great because I have access to all the data that I could ever possibly need. And I think like many enablement leaders, I bucket our metrics into leading and lagging indicators of success. And leading and lagging indicators of influence, which I don’t think is a unique model to be using, but it’s a very effective model. So the leading is the data that myself and my enablement team, we can directly tie back to our enablement efforts. Things like attendance and completion rates and challenge scores, and even conversational intelligence trackers within our CI system. Those are really easy metrics for us to. Be able to track to start to tell part of the story. I think the lagging indicators are so important to prove our value to the larger business and to continuously show how we are aligned with whatever it is that the business is trying to focus on. And those lagging indicators are ones that we would also love to be like, yes, enablement. Had a direct influence on, but there’s other, you know, influences that come into play there. I often find that those lagging indicators are the hardest. Bits of data to get access to in the business. But as I mentioned, I have like the greatest revenue operations team. And specifically, I have a colleague on my team, a coworker, Trevor, who builds out the most brilliant lagging indicator dashboards. He even does a good job of like bringing in the leading indicators to that dashboard. And this is what we really use month over month enablement strategy. So these are things like deal velocity. These are things like the financials of like, if we’re doing enablement on a specific product line, are we seeing an uptick in the revenue that’s coming in from those product lines? Our pipeline data, even outreach data and data specific to our tools. We really deep dive into this data month over month. And we actually have like a monthly data review session where we look at our leading indicators, lagging indicators, try and drive correlation, but also. It’s not just for proving out the efficacy of our efforts. It’s really figuring out, okay, based on this data, where is it that we are going to go next? And I think when we’re looking at data, we do it in two ways. One, we have quarterly priority sessions amongst my enablement team, where we all sit down and we figure out, okay, what are the biggest like lagging indicator data drivers that we need to have influence on this quarter? What’s data telling us? Is it retention? Is it pipeline? Whatever that is. And then month over month we look a little bit more granular at the data to figure out are we actually having the impact that we need to have. From a business perspective. SS: I think those are definitely some of the key metrics as change efforts. Typically, though, they kind of progress through various stages and often require time to fully implement. How do you maintain momentum as new processes become solidified in the long term? JS: Yeah, we love to take an ever-boarding approach. So we onboarding new people. We also do it when we’re launching large-scale enablement efforts. I actually think the key to making enablement sticky is providing leaders with the resources to coach on this on an ongoing basis. We are a small team. We can’t scale to have on one conversations with everyone and figure out where it’s falling short, and where we need to make adjustments. Perhaps Mike is better than Anthony. We don’t have those resources to be able to get really granular into the people aspect of this. But the managers do and that’s their job and they want to be doing this. So we like to think about when we launch an enablement series, Look at the data first. We figure out why are we doing this enablement. Is it necessary? Are we doing this because we have our own agenda or does the data align with us? We then meet with the managers first and we actually run almost the same version of the enablement session with them with some caveats why are we running this? What’s the purpose of this? What are we going to be presenting? And then the last part of that is managers, what do we need from you post enablement? Maybe it’s that we need you to listen to one call per rep per month and provide them feedback in the system so that we can gather that data and see how this is sticking. Maybe it’s that we have created a coaching template so that you can have these conversations in your one-to-one. And by the way, upload those into one of our systems, obviously on a private basis, so that we can review those as well. We want to be able to provide the leaders with the resources that they need to help us make enablement sticky. And then we run the enablement session for their people. And then when we’re doing the expertise exchange, we also have a one-month retro with the leaders where we talk about what are you seeing in the field. What’s working? What’s not working? A very similar exchange session that we do for our. People but with managers. We want the managers to have a voice in where we go next as well. SS: I love that. Last question, Jenna. Looking ahead, how do you envision evolving your enablement strategy to keep pace with your business’s growth? JS: Yeah, absolutely. We actually just had our enablement strategy meeting for 2025 and really starting to look at the data. And actually, as of recently, my team acquired product training as well. So we now have an even better opportunity to kind of align all training across the business and make sure that we’re all working in a singular direction. Although for a lot of new teams as well too, right, we’re not just focused on revenue enablement now. We’re also focused on the technical teams from a product training perspective. So, alignment across the org and how we approach enablement. I’m also selfishly very excited about this because I get a lot of new unique perspectives from my team considering I have new folks on my team now as well who have had a different view vantage point of enablement across the org. But also I want my team to continuously get to a proactive state. And I think we can only get there by being brutally honest about our current progress and using data to drive decisions. I love what my team has done thus far in using data, but The data is one piece. We need to storytell with the data. We really need to make it make sense for everyone else within the business. And we need to make it make sense for us so that we can be proactive. We have like one rule on my team and it’s, you’re not allowed to bring an ego to work and think that your way is the best way. And during our enablement strategy meeting, I started off with everyone needing to challenge us, and challenge me as a leader. I don’t know the best way forward all the time. You all have great ideas that I have never even thought of. We all need to continue to challenge each other, use data to make data-driven decisions, and really continue to retro and think about, did this work? Was this effective? Was this not effective? All while being proactive and really, you know, scaling our team. It’s like an impossible task that we have as enablement, but I think it’s possible with the right people and with the right strategy. SS: I’m excited to see where you all go. Thank you, Jenna, so much for this. JS: Yeah, thank you so much for having me. It was great. SS: And thank you to our audience for listening to this episode of the Win-Win Podcast. Be sure to tune in next time for more insights on how you can maximize enablement success with Highspot.
We chat about Starbucks coming to Perth, and booking ADRs being way too easy this time. May contain traces of succession.
In this episode of The STR Data Lab, Jamie and Scott broadcast live from the VRMA conference in Phoenix, Arizona, where they break down the key issues shaping the short-term rental industry today. They emphasize why events like VRMA are more important than ever, offering a crucial space for the industry to come together and tackle pressing challenges head-on. The conversation kicks off with the aftermath of hurricanes Helena and Milton, which caused a wave of cancellations across Florida and North Carolina. Asheville alone saw over 85,000 nights canceled, while Atlanta experienced a 50% spike in bookings as people sought temporary accommodations. These disruptions are expected to lead to a dip in home prices and rising insurance premiums across Florida, adding new challenges for property owners. Jamie and Scott then shift focus to the U.S. market's September performance, which fell short of expectations with a modest 2.9% increase in nights booked. The growth in supply is slowing, particularly in urban areas, where a 3.1% decline reflects ongoing struggles with regulatory issues, weak demand, and heightened competition from hotels—leading to closures like Frontdesk. On the bright side, ADRs were up 2.7% in September, and October is off to a strong start, with demand fueled by events like Halloween and solid holiday bookings on the horizon. Jamie wraps up the episode by celebrating his first short-term rental booking and sharing a sneak peek of his new YouTube series, which you can catch on the AirDNA YouTube channel. Don't miss this episode—it's packed with valuable insights! ~~~~ Signup for AirDNA for FREE
SIE exam overview part 1 Podcast episode major securities regulations (Securities Acts of 1933, 1934, etc.) and their key provisions - Detailed explanations were provided on different types of securities including stocks, bonds, options, and their characteristics - Math concepts related to securities pricing, yields, and options were demonstrated - Practice questions were reviewed to show how concepts may be tested on the SIE exam Topics Securities Regulations - Securities Act of 1933 covers primary market and new securities issuance - Securities Act of 1934 created the SEC and regulates the secondary market - Other key acts include Investment Company Act of 1940 and Investment Advisers Act of 1940 Equity Securities - Common stock provides ownership, voting rights, potential dividends - Preferred stock provides fixed dividends, no voting rights - ADRs allow trading foreign stocks on US exchanges - Rights offerings allow existing shareholders to maintain ownership percentage Debt Securities - Corporate bonds, municipal bonds, and US Treasuries discussed - Key concepts: par value, coupon rate, yield, call provisions - Risks include interest rate risk, credit risk, reinvestment risk Options - Calls provide right to buy, puts provide right to sell - Key terms: strike price, premium, expiration, intrinsic value - Buying options limits risk to premium paid - Selling options has potentially unlimited risk Calculations - Stock splits, dividends, and rights offerings - Bond yields - current yield, yield to maturity, yield to call - Options pricing and breakeven points Next Steps - Review practice questions, especially on topics like options and bond yields - Focus on memorizing key regulatory acts and their provisions - Practice calculations for stock splits, dividends, bond yields, etc. - Review risks associated with different security types #sieexam #sieexam #finra
Mike, Pam, and Rikki are here today answering your awesome Listener Questions! Today, we start off with a very quick discussion about the Cake Bake Shop prices (which we will talk more about on Friday), and then answer questions about what to expect at the Wine & Dine Half-Marathon Post-Race Party at Epcot, give suggestions for ADRs at Disneyland for a first-time trip on New Year's Eve, talk making Candlelight Processional Dining Package plans, and read an email with a theory on why a certain Disney Cruise Line ship might be your favorite! Please come join the BOGP Clubhouse on our Discord channel at www.beourguestpodcast.com/clubhouse! Thank you so much for your support of our podcast! Become a Patron of the show at www.Patreon.com/BeOurGuestPodcast. Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
In this compilation program, Justin Klein and Luke Guerrero field a variety of finance and investment questions from callers across the United States and around the world.Today's Stocks & Topics: Finance Books, ADRs vs. Buying Foreign Stocks, Buying in Credit Card Companies, KPP Management of ETFs, Asset Allocation, Annuities, Investing in Other Markets, Taking Profits, Insider Buying, Transferring 401k to a Roth 401k, I-R-A Money, Portfolio Diversification, Balancing a Portfolio, What's Wrong With Edward Jones, 401 and 427 Plans, Dual Direction Funds, Expense Ratios.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
In this special episode of Good Morning Hospitality EU, Leo Walton and Simon Lehmann, CEO of AJL Atelier, explore the evolving landscape of the European short-term rental market. Simon shares his expert insights on the ongoing fragmentation of the market, emphasizing how the sector remains hyperlocal, with even the largest players holding a small market share. He highlights the role of technology in allowing smaller property managers to compete while addressing the growing impact of regulations, particularly in urban areas, and the challenges they pose to operators. Simon predicts tougher times ahead for the industry, with falling ADRs and an oversupply of properties. However, he also identifies opportunities for growth in budget travel and niche sectors like camping. The discussion wraps up with a look at how AI could transform property search processes and optimize guest experiences. OTAs remain dominant but face potential disruption from niche platforms. Tune in to learn how property managers can navigate these changes and position themselves for success in 2024 and beyond. — Good Morning Hospitality is part of the Hospitality.FM podcast network and a Hospitality.FM Original. If you like this podcast, then you'll also love Behind The Stays with Zach Busekrus, which comes out every Tuesday & Friday, wherever you get your podcasts! This show is structured to cover industry news in travel and hospitality and is recorded live every Monday morning at 7 a.m. PST/10 a.m. EST. So make sure you tune in during our live show on our social media channels or YouTube and join the conversation live! Thank you to all of the Hospitality.FM Partners that help make this show possible, and if you have any press you want covered during the show, fill out this form! Learn more about your ad choices. Visit megaphone.fm/adchoices
Topics covered in this episode: Architecture Decision Records (ADRs) narwhals: extremely lightweight compatibility layer between dataframes Microsoft wants Three Mile Island to fuel its AI power needs zsh-in-docker Extras Joke Watch on YouTube About the show Sponsored by ScoutAPM: pythonbytes.fm/scout Connect with the hosts Michael: @mkennedy@fosstodon.org Brian: @brianokken@fosstodon.org Show: @pythonbytes@fosstodon.org Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Architecture Decision Records (ADRs) Suggested by Christian Gesell Documenting Architecture Decisions Mychael Nygard Original article from 2011 Why you should be using architecture decision records to document your project Red Hat Includes a quick overview and links to some templates Notes so far Writing this out helps me solidify my thinking about a problem. I'm doing this both before starting, and while implementing a first draft GitHub and GitLab render markdown so well that generating a docs site is unnecessary, just throwing these files in something like docs/adr is enough. The lightweight process is enough but not too much. I've already filled out None for lots of sections, like “options considered” I'm still playing with what level of decision should have an ADR. My template that I've been using so far Saved in 000-adr-template.md For easy copy/paste/modify for new records. File name is something like 001-some-change.md Michael #2: narwhals: extremely lightweight compatibility layer between dataframes Recently had Marco on Talk Python to discuss Primarily for library creators who want to support interacting with multiple data frame libraries (.e.g. Pandas & Polars) Just use a subset of the Polars API Brian #3: Microsoft wants Three Mile Island to fuel its AI power needs “Microsoft just signed a deal to revive the shuttered Three Mile Island nuclear power plant. If approved by regulators, the software maker would have exclusive rights to 100 percent of the output for its AI data center needs.” Also ran on CNN and other sources: Three Mile Island is reopening and selling its power to Microsoft Three Mile Island was the site of the worst nuclear disaster in the US, when one of two reactors experienced a partial meltdown, in 1979. It was still operating up until 2019, and now expected to re-open in 2028 Will be renamed “Crane Clean Energy Center” related The Department of Energy Wants You to Know Your Conservation Efforts Are Making a Difference “By switching all the lightbulbs in your house to LED, you saved enough energy for a self-driving car to make an unprotected lefthand turn across three lanes of traffic.” “We know you adopted energy-saving practices to help conserve our planet's resources and bring down our collective carbon footprint, but what you ultimately accomplished is just as important: helping AI do something menial and stupid.” Michael #4: zsh-in-docker Install Zsh, Oh My Zsh and plugins inside a Docker container with one line! Yes docker containers should be light, but also, think of how painful it can be when you run into trouble. With Oh My ZSH, you get a nice experience when you have to result to docker exec -it CONTAINER zsh Just enter a single command in your docker file: RUN sh -c "$(wget -O- https://github.com/deluan/zsh-in-docker/releases/download/v1.2.0/zsh-in-docker.sh)" -- -t robbyrussell Extras Michael: self-hosting mkennedy.codes Loren's journey to developer It's time to stop using Python 3.8 Sonoma → Sequoia → Sonoma (yikes!) Passkeys, maybe they will work out if we don't let them become lock-in (bitwarden's support) Joke: How to Monetize a Blog Don't forget to click on the bottom link: Credits / how this was made
This is the Live Call-in Show from this past Sunday night, September 1, 2024! Tonight, Mike was in the Studio alone as Scott was visiting Nashville with some friends, but Scott does call-in to share some of his "ghostly" fun he is having in Music City this weekend, and we also talk about his upcoming trip to The Cabins at Fort Wilderness and why you shouldn't stress so much about ADRs! We also discuss the start to the runDisney season in Disneyland this weekend and the Oogie Boogie Bash at DCA with callers during the show as well! Come join us in the BOGP Clubhouse this week at www.beourguestpodcast.com/discord. Please visit our website at www.beourguestpodcast.com. Thank you so much for your support of our podcast! Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Become a patron of the Be Our Guest Podcast over at www.patreon.com/BeOurGuestPodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
Mike and Pam are here today answering your amazing trip-planning questions on the show! Today, we get a question about options for dining on a solo trip for the first time, getting to pre-park opening ADRs at the Magic Kingdom, looking for the best steak on-property at Walt Disney World, thoughts on where to stay for first runDisney experience at Springtime Surprise Weekend, and much more on today's show! Please come join the BOGP Clubhouse on our Discord channel at www.beourguestpodcast.com/discord! Thank you so much for your support of our podcast! Become a Patron of the show at www.Patreon.com/BeOurGuestPodcast. Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
Hell investiert - Erfolgreich mit Gold, Immobilien, ETFs & Co.
Gibt es für russische ADRs noch Hoffnung? Dem gehe ich heute nach, denn sowohl die Schutzgemeinschaft der Kleinanleger als auch eine Anfrage an die Bundesregierung haben neue Erkenntnisse geliefert. ► „Buy The DIP“ mit Lars Erichsen, Timo Baudzus und mir findet ihr hier: https://buythedip.podigee.io/ ► NEU: Meine exklusive Vermögens-Strategie –
In this episode, Leo Walton and Damien Sheridan explore the latest trends in the short-term rental market, focusing on how hosts can stand out by offering thoughtful amenities even in budget accommodations. They discuss the recent European market data showing a slight decline in ADRs despite strong demand and consider the impact of climate change on travel patterns. The episode also highlights the growing significance of the US market for OTAs, with Booking.com's latest marketing stunt featuring rapper Ludacris offering a unique stay experience in his Atlanta mansion. — Good Morning Hospitality is part of the Hospitality.FM podcast network and a Hospitality.FM Original. If you like this podcast, then you'll also love Behind The Stays with Zach Busekrus, which comes out every Tuesday & Friday, wherever you get your podcasts! This show is structured to cover industry news in travel and hospitality and is recorded live every Monday morning at 7 a.m. PST/10 a.m. EST. So make sure you tune in during our live show on our social media channels or YouTube and join the conversation live! Thank you to all of the Hospitality.FM Partners that help make this show possible, and if you have any press you want covered during the show, fill out this form! Learn more about your ad choices. Visit megaphone.fm/adchoices
In this compilation program, Justin Klein and Luke Guerrero field a variety of finance and investment questions from callers across the United States and around the world.Today's Stocks & Topics: Finance Books, ADRs vs. Buying Foreign Stocks, Buying in Credit Card Companies, KPP Management of ETFs, Asset Allocation, Annuities, Investing in Other Markets, Taking Profits, Insider Buying, Transferring 401k to a Roth 401k, I-R-A Money, Portfolio Diversification, Balancing a Portfolio, What's Wrong With Edward Jones, 401 and 427 Plans, Dual Direction Funds, Expense Ratios.Our Sponsors:* Check out Fabric: fabric.com/INVESTTALK* Check out Moorings: moorings.com* Check out eBay Auto: www.ebay.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
SIE exam overview part 1 Podcast episode major securities regulations (Securities Acts of 1933, 1934, etc.) and their key provisions - Detailed explanations were provided on different types of securities including stocks, bonds, options, and their characteristics - Math concepts related to securities pricing, yields, and options were demonstrated - Practice questions were reviewed to show how concepts may be tested on the SIE exam Topics Securities Regulations - Securities Act of 1933 covers primary market and new securities issuance - Securities Act of 1934 created the SEC and regulates the secondary market - Other key acts include Investment Company Act of 1940 and Investment Advisers Act of 1940 Equity Securities - Common stock provides ownership, voting rights, potential dividends - Preferred stock provides fixed dividends, no voting rights - ADRs allow trading foreign stocks on US exchanges - Rights offerings allow existing shareholders to maintain ownership percentage Debt Securities - Corporate bonds, municipal bonds, and US Treasuries discussed - Key concepts: par value, coupon rate, yield, call provisions - Risks include interest rate risk, credit risk, reinvestment risk Options - Calls provide right to buy, puts provide right to sell - Key terms: strike price, premium, expiration, intrinsic value - Buying options limits risk to premium paid - Selling options has potentially unlimited risk Calculations - Stock splits, dividends, and rights offerings - Bond yields - current yield, yield to maturity, yield to call - Options pricing and breakeven points Next Steps - Review practice questions, especially on topics like options and bond yields - Focus on memorizing key regulatory acts and their provisions - Practice calculations for stock splits, dividends, bond yields, etc. - Review risks associated with different security types #sieexam #sieexam #finra
Pharmacogenomics plays a critical role in personalised medicine, as some adverse drug reactions are genetically determined. Adverse drugs reactions (ADRs) account for 6.5% of hospital admissions in the UK, and the application of pharmacogenomics to look at an individuals response to drugs can significantly enhance patient outcomes and safety. In this episode, our guests discuss how genomic testing can identify patients who will respond to medications and those who may have adverse reactions. We hear more about Genomics England's collaboration with the Medicines and Healthcare products Regulatory Agency in the Yellow Card Biobank and our guests discuss the challenges of implementing pharmacogenomics into the healthcare system. Our host Vivienne Parry, Head of Public Engagement at Genomics England, is joined by Anita Hanson, Research Matron and the Lead Research Nurse for clinical pharmacology at Liverpool University Hospitals NHS Foundation Trust, and Professor Bill Newman, Professor of translational genomic medicine at the Manchester Center for Genomic Medicine, and Professor Matt Brown, Chief Scientific Officer at Genomics England. "I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record." To learn more about Jane's lived experience with Stevens-Johnson syndrome, visit The Academy of Medical Sciences' (AMS) YouTube channel. The story, co-produced by Areeba Hanif from AMS, provides an in-depth look at Jane's journey. You can watch the video via this link: https://www.youtube.com/watch?v=v4KJtDZJyaA Want to learn more about personalised medicine? Listen to our Genomics 101 episode where Professor Matt Brown explains what it is in less than 5 minutes: https://www.genomicsengland.co.uk/podcasts/genomics-101-what-is-personalised-medicine You can read the transcript below or download it here: https://www.genomicsengland.co.uk/assets/documents/Podcast-transcripts/Can-genomic-testing-prevent-adverse-drug-reactions.docx Vivienne: Hello and welcome to Behind the Genes. Bill: What we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So, a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing. Vivienne: My name's Vivienne Parry and I'm head of public engagement at Genomics England, and today we'll be discussing the critical role of pharmacogenomics in personalised medicine, highlighting its impact on how well medicines work, their safety, and on patient care. I'm joined today by Professor Bill Newman, professor of translational genomic medicine at the Manchester Centre for Genomic Medicine, Anita Hanson, research matron, a fabulous title, and lead research nurse for clinical pharmacology at the Liverpool University Hospital's NHS Foundation Trust, and Professor Matt Brown, chief scientific officer for Genomics England. And just remember, if you enjoy today's episode, we'd love your support, so please like, share and rate us on wherever you listen to your podcasts. So, first question to you, Bill, what is pharmacogenomics? Bill: Thanks Viv. I think there are lots of different definitions, but how I think of pharmacogenetics is by using genetic information to inform how we prescribe drugs, so that they can be safer and more effective. And we're talking about genetic changes that are passed down through families, so these are changes that are found in lots of individuals. We all carry changes in our genes that are important in how we transform and metabolise medicines, and how our bodies respond to them. Vivienne: Now, you said pharmacogenetics. Is it one of those medicine things like tomato, tomato, or is there a real difference between pharmacogenetics and pharmacogenomics? Bill: So, people, as you can imagine, do get quite irate about this sort of thing, and there are lots of people that would contest that there is a really big important difference. I suppose that pharmacogenetics is more when you're looking at single changes in a relatively small number of genes, whereas pharmacogenomics is a broader definition, which can involve looking at the whole genome, lots of genes, and also whether those genes are switched on or switched off, so the expression levels of those genes as well would encompass pharmacogenomics. But ultimately it's using genetic information to make drug prescription safer and more effective. Vivienne: So, we're going to call it pharmacogenomics and we're talking about everything, that's it, we'll go for it. So Matt, just explain if you would the link between pharmacogenomics and personalised medicine. And I know that you've done a big Genomics 101 episode about personalised medicine, but just very briefly, what's the link between the two? Matt: So, personalised medicine's about using the right dose of the right drug for the right individual. And so pharmacogenomics helps you with not only ensuring that you give a medication which doesn't cause problems for the person who receives it, so an adverse drug reaction, but also that they're actually getting the right dose. Of course, people's ability to metabolise, activate and respond to drugs genetically is often genetically determined, and so sometimes you need to adjust the dose up or down according to a person's genetic background. Vivienne: Now, one of the things that we've become very aware of is adverse drug reactions, and I think they account for something like six and a half percent of all hospital admissions in the UK, so it's absolutely huge. Is that genetically determined adverse drug reactions? Matt: So, the answer to that is we believe so. There's quite a bit of data to show that you can reduce the risk of people needing a hospital admission by screening genetic markers, and a lot of the very severe reactions that lead to people being admitted to hospital are very strongly genetically determined. So for example, there are HLA types that affect the risk of adverse drug reactions to commonly used medications for gout, for epilepsy, some HIV medications and so on, where in many health services around the world, including in England, there are already tests available to help prevent those leading to severe reactions. It's likely though that actually the tests we have available only represent a small fraction of the total preventable adverse drug reactions were we to have a formal pre-emptive pharmacogenomics screening programme. Vivienne: Now, I should say that not all adverse drug reactions are genetic in origin. I mean, I remember a rather nasty incident on the night when I got my exam results for my finals, and I'd actually had a big bee sting and I'd been prescribed antihistamines, and I went out and I drank rather a lot to celebrate, and oh my goodness me, I was rather ill [laughter]. So, you know, not all adverse drug reactions are genetic in origin. There are other things that interact as well, just to make that clear to people. Matt: Yes, I think that's more an interaction than an adverse drug reaction. In fact frankly, the most common adverse drug reaction in hospitals is probably through excess amounts of water, and that's not medically determined, that's the prescription. Vivienne: Let me now come to Anita. So, you talk to patients all the time about pharmacogenomics in your role. You've been very much involved in patient and public involvement groups at the Wolfson Centre for Personalised Medicine in Liverpool. What do patients think about pharmacogenomics? Is it something they welcome? Anita: I think they do welcome pharmacogenomics, especially so with some of the patients who've experienced some of the more serious, life threatening reactions. And so one of our patients has been doing some work with the Academy of Medical Sciences, and she presented to the Sir Colin Dollery lecture in 2022, and she shared her story of having an adverse drug reaction and the importance of pharmacogenomics, and the impact that pharmacogenomics can have on patient care. Vivienne: Now, I think that was Stevens-Johnson syndrome. We're going to hear in a moment from somebody who did experience Stevens-Johnson's, but just tell us briefly what that is. Anita: Stevens-Johnson syndrome is a potentially life threatening reaction that can be caused by a viral infection, but is more commonly caused by a medicine. There are certain groups of medicines that can cause this reaction, such as antibiotics or anticonvulsants, nonsteroidal anti-inflammatories, and also a drug called allopurinol, which is used to treat gout. Patients have really serious side effects to this condition, and they're often left with long-term health complications. The morbidity and mortality is considerable as well, and patients often spend a lot of time in hospital and take a long time to recover. Vivienne: And let's now hear from Jane Burns for someone with lived experience of that Stevens-Johnson syndrome. When Jane Burns was 19, the medicine she took for her epilepsy was changed. Jane: I remember waking up and feeling really hot, and I was hallucinating, so I was taken to the Royal Liverpool Hospital emergency department by my parents. When I reached A&E, I had a temperature of 40 degrees Celsius. I was given Piriton and paracetamol, and the dermatologist was contacted. My mum had taken my medication to hospital and explained the changeover process with my epilepsy medication. A decision was made to discontinue the Tegretol and I was kept in for observation. Quite rapidly, the rash was changing. Blisters were forming all over my body, my mouth was sore and my jaw ached. My temperature remained very high. It was at this point that Stevens-Johnson syndrome, or SJS, was diagnosed. Over the next few days, my condition deteriorated rapidly. The rash became deeper in colour. Some of the blisters had burst, but some got larger. I developed ulcers on my mouth and it was extremely painful. I started to lose my hair and my fingernails. As I had now lost 65 percent of my skin, a diagnosis of toxic epidermal necrolysis, or TEN, was made. Survivors of SJS TEN often suffer with long-term visible physical complications, but it is important to also be aware of the psychological effects, with some patients experiencing post-traumatic stress disorder. It's only as I get older that I realise how extremely lucky I am to have survived. Due to medical and nursing expertise, and the research being conducted at the time, my SJS was diagnosed quickly and the medication stopped. This undoubtedly saved my life. Vivienne: Now, you've been looking at the development of a passport in collaborating with the AMS and the MHRA. Tell me a bit more about that. Anita: Yes, we set up a patient group at the Wolfson Centre for Personalised Medicine approximately 12 years ago, and Professor Sir Munir Pirmohamed and I, we wanted to explore a little bit more about what was important to patients, really to complement all the scientific and clinical research activity within pharmacogenomics. And patients recognised that, alongside the pharmacogenomic testing, they recognised healthcare professionals didn't really have an awareness of such serious reactions like Stevens-Johnson syndrome, and so they said they would benefit from having a My SJS Passport, which is a booklet that can summarise all of the important information about their care post-discharge, and this can then be used to coordinate and manage their long-term healthcare problems post-discharge and beyond. And so this was designed by survivors for survivors, and it was then evaluated as part of my PhD, and the findings from the work suggest that the passport is like the patient's voice, and it really does kind of validate their diagnosis and raises awareness of SJS amongst healthcare professionals. So, really excellent findings from the research, and the patients think it's a wonderful benefit to them. Vivienne: So, it's a bit like a kind of paper version of the bracelet that you sometimes see people wearing that are on steroids, for instance. Anita: It is like that, and it's wonderful because it's a handheld source of valuable information that they can share with healthcare professionals. And this is particularly important if they're admitted in an emergency and they can't speak for themselves. And so the passport has all that valuable information, so that patients aren't prescribed that drug again, so it prevents them experiencing a serious adverse drug reaction again. Vivienne: So, Stevens-Johnson, Bill, is a really scary side effect, but what about the day to day benefits of pharmacogenomics for patients? Bill: So, what we've seen is that the limited adoption so far in the UK and other countries has focused particularly on severe adverse drug reactions. They've been easier to identify and there's a clear relationship between some drugs and some genetic changes where that information is useful. So a good example has been the recent adoption of pharmacogenetic testing for a gene called DPYD for patients undergoing cancer treatment, particularly breast and bowel cancer. And if you have an absence of the enzyme that that gene makes, if you're given that treatment, then you can end up on intensive care and die, so it's a really significant side effect. But as you say, the most common side effects aren't necessarily fatal, but they can have a huge impact upon people and on their wellbeing. And it's not just in terms of side effects. It's in terms of the effectiveness of the medicine. Because if a person is prescribed a medicine that doesn't or isn't going to work for them then it can take them longer to recover, to get onto the right medicine. That can have all sorts of detrimental effects. And so when we're thinking about introducing pharmacogenetics more broadly rather than just on a single drug or a single gene basis, we're thinking about that for common drugs like antidepressants, painkillers, statins, the drugs that GPs are often prescribing on a regular basis to a whole range of patients. Vivienne: So, to go back to you, Anita, we're really talking about dose here, aren't we, whether you need twice the dose or half the dose depending on how quickly your body metabolises that particular medicine. How do patients view that? Anita: Well, the patient in question who presented for the Academy of Medical Sciences, I mean, her take on this was, she thinks pharmacogenetics is wonderful because it will allow doctors and nurses to then prescribe the right drug, but also to adapt the dose accordingly to make sure that they get the best outcome, which provides the maximum benefit while also minimising any potential harm. And so from her perspective, that was one of the real benefits of pharmacogenomics. But she also highlighted about the benefits for future generations, the fear of her son taking the same medicine and experiencing the same reaction. And so I think her concerns were, if we have pharmacogenetic testing for a panel of medicines, as Bill mentioned then, then perhaps this would be fantastic for our children as they grow up, and we can identify and predict and prevent these type of reactions happening to future generations. Vivienne: And some of these drugs, Bill, are really very common indeed, something like codeine. Just tell us about codeine, ‘cos it's something – whenever I tell this to friends [laughter], they're always completely entranced by the idea that some people don't need nearly as much codeine as others. Bill: Yeah, so codeine is a drug that's very commonly used as a painkiller. To have its real effect, it needs to be converted in the body to a different drug called morphine, and that is done by an enzyme which is made by a gene called CYP2D6. And we all carry changes in CYP2D6, and the frequency of those variants, whether they make the gene work too much or whether they make it work too little, they vary enormously across the world, so that if you go to parts of Africa, about 30 percent of the population will make more of the CYP2D6, and so they will convert the codeine much more quickly, whereas if you go to the UK, maybe up to ten percent of the white population in the UK just won't be converting codeine to morphine at all, so they won't get any benefit from the drug. So at both ends, you have some people that don't respond and some people that respond a little bit too much so that they need either an alternative drug or they need a different dose. Vivienne: So, all those people who say, you know, “My headache hasn't been touched by this painkiller,” and we say, “What a wimp you're being,” actually, it's to do with genetics. Bill: Yeah, absolutely. There's a biological reason why people don't – not for everybody, but for a significant number of people, that's absolutely right, and we can be far more tailored in how we prescribe medication, and get people onto painkillers that work for them much more quickly. Vivienne: And that's so interesting that it varies by where you come from in the world, because that means we need to give particular attention – and I'm thinking, Anita, to working with patients from different community groups, to make sure that they understand the need for pharmacogenomics. Anita: I think that's really important, Vivienne, and I think we are now having discussions with the likes of Canada SJS awareness group, and also people have been in touch with me from South Africa because people have requested the passport now to be used in different countries, because they think it's a wonderful tool, and it's about raising awareness of pharmacogenomics and the potential benefits of that, and being able to share the tools that we've got to help patients once they've experienced a serious reaction. Vivienne: So, pharmacogenomics clearly is important in the prevention of adverse drug reactions, better and more accurate prescribing, reduced medicines wastage. Does this mean that it's also going to save money, Bill, for the NHS? Bill: Potentially. It should do if it's applied properly, but there's lots of work to make sure that not only are we using the right evidence and using the right types of tests in the laboratory, but we're getting the information to prescribers, so to GPs, to pharmacists, to hospital doctors, in a way that is understandable and meaningful, such that they can then act upon that information. So, the money will only be saved and then can be reused for healthcare if the whole process and the whole pathway works, and that information is used effectively. Vivienne: So, a lot of research to make sure that all of that is in place, and to demonstrate the potential cost savings. Bill: Yes. I mean, there are very nice studies that have been done already in parts of the world that have shown that the savings that could be accrued for applying pharmacogenetics across common conditions like depression, like in patients to prevent secondary types of strokes, are enormous. They run into hundreds of millions of pounds or dollars. But there is an initial investment that is required to make sure that we have the testing in place, that we have the digital pathways to move the information in place, and that there's the education and training, so that health professionals know how to use the information. But the potential is absolutely enormous. Vivienne: Matt, can I turn now to the yellow card. So, people will be very familiar with the yellow card system. So, if you have an adverse reaction, you can send a yellow card in – I mean, literally, it is a yellow card [laughter]. It does exactly what it says on the tin. You send a yellow card to the MHRA, and they note if there's been an adverse effect of a particular medicine. But Genomics England is teaming up with the MHRA to do something more with yellow cards, and we're also doing this with the Yellow Card Biobank. Tell us a bit more. Matt: So, yellow card's a great scheme that was set up decades ago, initially starting off, as you said, with literally yellow cards, but now actually most submissions actually come online. And it's important to note that submissions can come not just from healthcare providers, but majority of submissions actually come from patients themselves, and that people should feel free, if they feel they've had an adverse drug reaction, to report that themselves rather than necessarily depending on a medical practitioner or the healthcare provider to create that report. So, Genomics England is partnering with the MHRA in building what's called the Yellow Card Biobank, the goal of which is to identify genetic markers for adverse drug reactions earlier than has occurred in the past, so that we can then introduce genetic tests to prevent these adverse drug reactions much sooner than has occurred previously. So, what we're doing is basically at the moment we're doing a pilot, but the ultimate plan is that in future, patients who report a serious adverse drug reaction through the Yellow Card Biobank will be asked to provide a sample, a blood sample, that we then screen. We do a whole genome sequence on it, and then combine these with patients who've had like adverse drug reactions and identify genetic markers for that adverse drug reaction medication earlier, that can then be introduced into clinical practice earlier. And this should reduce by decades the amount of time between when adverse drug reactions first start occurring with medications and us then being able to translate that into a preventative mechanism. Vivienne: And will that scheme discover, do you think, new interactions that you didn't know about before? Or do you expect it to turn up what you already know about? Matt: No, I really think there's a lot of discovery that is yet to happen here. In particular, even for drugs that we know cause adverse drug reactions, mostly they've only been studied in people of European ancestry and often in East Asian ancestry, but in many other ancestries that are really important in the global population and in the UK population, like African ancestry and South Asian ancestries, we have very little data. And even within Africa, which is an area which is genetically diverse as the rest of the world put together, we really don't know what different ethnicities within Africa, actually what their genetic background is with regard to adverse drug reactions. The other thing I'd say is that there are a lot of new medications which have simply not been studied well enough. And lastly, that at the moment people are focused on adverse drug reactions being due to single genetic variants, when we know from the model of most human diseases that most human diseases are actually caused by combinations of genetic variants interacting with one another, so-called common disease type genetics, and that probably is similarly important with regard to pharmacogenomics as it is to overall human diseases. That is, it's far more common that these are actually due to common variants interacting with one another rather than the rare variants that we've been studying to date. Vivienne: So, it's a kind of cocktail effect, if you like. You know, you need lots of genes working together and that will produce a reaction that you may not have expected if you'd looked at a single gene alone. Matt: That's absolutely correct, and there's an increasing amount of evidence to show that that is the case with medications, but it's really very early days for research in that field. And the Yellow Card Biobank will be one of many approaches that will discover these genetic variants in years to come. Vivienne: Now, Matt's a research scientist. Bill, you're on the frontline in the NHS. How quickly can this sort of finding be translated into care for people in the NHS? Bill: So, really quickly is the simple answer to that, Viv. If we look at examples from a number of years ago, there's a drug called azathioprine that Matt has used lots in some of his patients. In rheumatology, it's used for patients with inflammatory bowel disease. And the first studies that showed that there was a gene that was relevant to having bad reactions to that drug came out in the 1980s, but it wasn't until well into this century, so probably 30-plus years later that we were routinely using that test in clinical medicine. So, there was an enormous lot of hesitancy about adopting that type of testing, and a bit of uncertainty. If you move forward to work that our colleague Munir Pirmohamed in Liverpool has done with colleagues in Australia like Simon Mallal around HIV medicine, there was this discovery that a drug called abacavir, that if you carried a particular genetic change, that you had a much higher risk of having a really severe reaction to that. The adoption from the initial discovery to routine, worldwide testing happened within four years. So, already we've seen a significant change in the appetite to move quickly to adopt this type of testing, and I see certainly within the NHS and within other health systems around the world, a real desire to adopt pharmacogenetics into routine clinical practice quickly and at scale, but also as part of a broader package of care, which doesn't just solely focus on genetics, but thinks about all the other parts that are important in how we respond to medication. So, making sure we're not on unusual combinations of drugs, or that we're taking our medicine at the right time and with food or not with food, and all of those other things that are really important. And if you link that to the pharmacogenetics, we're going to have a much safer, more effective medicines world. Vivienne: I think one of the joys of working at Genomics England is that you see some of this work really going into clinical practice very fast indeed. And I should say actually that the Wolfson Centre for Personalised Medicine, the PPI group that Anita looks after so well, they've been very important in recruiting people to Yellow Card Biobank. And if anyone's listening to this, Matt, and wants to be part of this, how do they get involved? Or is it simply through the yellow card? Matt: So at the moment, the Yellow Card Biobank is focusing on alopurinol. Vivienne: So, that's a medicine you take for gout. Matt: Which I use a lot in my rheumatology clinical practice. And direct acting oral anticoagulants, DOACs, which are used for vascular disease therapies and haemorrhage as a result of that. So, the contact details are available through the MHRA website, but I think more importantly, it's just that people be aware of the yellow card system itself, and that if they do experience adverse drug reactions, that they do actually complete a report form, ‘cos I think still actually a lot of adverse drug reactions go unreported. Vivienne: I'm forgetting of course that we see Matt all the time in the Genomics England office and we don't think that he has any other home [laughter] than Genomics England, but of course he still sees some patients in rheumatology clinic. So, I want to now look to the future. I mean, I'm, as you both know, a huge enthusiast for pharmacogenomics, ‘cos it's the thing that actually, when you talk to patients or just the general public, they just get it straight away. They can't think why, if you knew about pharmacogenomics, why you wouldn't want to do it. But it's not necessarily an easy thing to do. How can we move in the future, Bill, to a more proactive approach for pharmacogenomics testing? Where would we start? Bill: Yes, so I think we've built up really good confidence that pharmacogenetics is a good thing to be doing. Currently, we're doing that predominantly at the point when a patient needs a particular medicine. That's the time that you would think about doing a genetic test. And previously, that genetic test would only be relevant for that specific drug. I think we're moving to a place where, rather than just doing that one test that might be relevant to one drug, we'd be able to do a test which at the same price would generate information that could be relevant at further points in your life if you were requiring different types of medicine. So, that information would then be available in your hospital record, in your GP record, that you could have access to it yourself. And then I think ultimately what we would really love to get to a point is where everybody across the whole population just has that information to hand when it's required, so that they're not waiting for the results of a genetic test, it's immediately within their healthcare record. That's what we'd call pre-emptive pharmacogenetic testing, and I think that's the golden land that we want to reach. Vivienne: So for instance, I might have it on my NHS app, and when I go to a doctor and they prescribe something, I show my app to the GP, or something pops up on the GP's screen, or maybe it's something that pops up on the pharmacist's screen. Bill: I think that's right. I think that's what we're looking to get to that point. We know that colleagues in the Netherlands have made some great progress at developing pathways around that. There's a lot of public support for that. And pharmacists are very engaged in that. In the UK, the pharmacists, over the last few years, have really taken a very active role to really push forward this area of medicine, and this should be seen as something that is relevant to all people, and all health professionals should be engaged with it. Vivienne: And on a scale of one to ten, how difficult is it going to be to implement in the NHS? Bill: So, that's a difficult question. I think the first thing is identifying what the challenges are. So I have not given you a number, I've turned into a politician, not answered the question. So, I think what has happened over the last few years, and some of our work within the NHS Network of Excellence in pharmacogenetics and some of the other programmes of work that have been going on, is a really good, honest look at what it is we need to do to try to achieve pharmacogenetics implementation and routine use. I don't think the challenge is going to be predominantly in the laboratory. I think we've got phenomenal laboratories. I think we've got great people doing great genetic testing. I think the biggest challenges are going to be about how you present the data, and that data is accessible. And then ensuring that health professionals really feel that this is information that isn't getting in the way of their clinical practice, but really making a difference and enhancing it, and of benefit both to the healthcare system but more importantly to the patients. Vivienne: Now, when I hear you both talk, my mind turns to drug discovery and research, and Matt, I'm quite sure that that's right at the top of your mind. Tell us how pharmacogenomics can help in drug discovery and research. Matt: So, pharmacogenomics, I think actually just genetic profiling of diseases in itself just to start off with is actually a really good way of identifying new potential therapeutic targets, and also from derisking drug development programmes by highlighting likely adverse drug reactions of medications that are being considered for therapeutic trials, or targets that are being considered for therapeutic development. Pharmacogenomics beyond that is actually largely about – well, it enables drug development programmes by enabling you to target people who are more likely to respond, and avoid people who are more likely to have adverse drug reactions. And so that therapeutic index of the balance between likely efficacy versus likely toxicity, genetics can really play into that and enable medications to be used where otherwise they might have failed. This is most apparent I think in the cancer world. A classic example there, for example, is the development of a class of medications called EGFR inhibitors, which were developed for lung cancer, and in the initial cancer trials, actually were demonstrated to be ineffective, until people trialled them in East Asia and found that they were effective, and that that turns out to be because the type of cancers that respond to them are those that have mutations in the EGFR gene, and that that's common in East Asians. We now know that, wherever you are in the world, whether you're East Asian or European or whatever, if you have a lung adenocarcinoma with an EGFR mutation, you're very likely to respond to these medications. And so that pharmacogenomic discovery basically rescued a class of medication which is now probably the most widely used medication for lung adenocarcinomas, so a huge beneficial effect. And that example is repeated across multiple different cancer types, cancer medication types, and I'm sure in other fields we'll see that with expansive new medications coming in for molecularly targeted therapies in particular. Vivienne: So, smaller and more effective trials rather than larger trials that perhaps seem not to work but actually haven't been tailored enough to the patients that are most likely to benefit. Matt: Yeah, well, particularly now that drug development programmes tend to be very targeted at specific genetic targets, pharmacogenetics is much more likely to play a role in identifying patients who are going to respond to those medications. So, I think many people in the drug development world would like to see that, for any significant drug development programme, there's a proper associated pharmacogenomic programme to come up with molecular markers predicting a response. Vivienne: We're going to wrap up there. Thank you so much to our guests, Bill Newman, Anita Hanson, Matt Brown, and our patient Jane Burns. Thank you so much for joining us today to discuss pharmacogenomics in personalised medicine, and the benefits, the challenges and the future prospects for integrating pharmacogenomics into healthcare systems. And if you'd like to hear more podcasts like this, please subscribe to Behind the Genes. It's on your favourite podcast app. Thank you so much for listening. I've been your host, Vivienne Parry. This podcast was edited by Bill Griffin at Ventoux Digital and produced by the wonderful Naimah. Bye for now.
Major AI companies are facing a critical shortage of training data as websites restrict access and high-quality sources become scarce. This emerging crisis is impacting industry leaders like OpenAI and Google, who are exploring solutions such as million-dollar deals with publishers and the generation of synthetic data. The shortage of training data could significantly reshape the AI landscape by 2026, raising questions about the future of AI development and the ethical use of data. Today's Stocks & Topics: UPS - United Parcel Service Inc. Cl B, Market Wrap, APTV - Aptiv PLC, ADRs vs. Buying Foreign Stocks, AI Data Crisis: Tech Giants Scramble for Solutions, TELL - Tellurian Inc., ANF - Abercrombie & Fitch Co., Hottest Job Market in a Generation Is Over, EL - Estee Lauder Cos. Cl A, Asset Allocation, SM - SM Energy Co., Corporate Carbon Credits, Investing in Other Markets, Target Audience: Xbox.Our Sponsors:* Check out eBay Auto: www.ebay.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast
In this episode, we review the pharmacology, pharmacokinetics, adverse effects, monitoring, medicinal chemistry, and more of loop diuretics. Key Concepts Loop diuretics (furosemide, torsemide, bumetanide, ethacrynic acid) are the most potent type of diuretic and are used to relieve edema. Loop diuretics cause an increased loss of sodium, chloride, potassium, hydrogen, magnesium, and calcium ions into the urine. Excessive loss of these ions manifests as hypokalemia, hypomagnesemia, and metabolic alkalosis. Loop diuretics have an S-shaped dose response curve – a minimum dose is required for diuresis and a “ceiling” effect occurs at higher doses (leading to more ADRs). Doses should be individualized based on the clinical response of the patient. Ethacrynic acid is incorrectly used in patients with a “sulfa” allergy. The other loop diuretics contain a sulfa moiety but are safe for use in patients with “sulfa” allergy (e.g. allergy to sulfamethoxazole-trimethoprim). The TRANSFORM-HF trial strongly suggests that there is no clinical difference between furosemide and torsemide. References Rachoin JS, Cerceo EA. Four nephrology myths debunked. J Hosp Med. 2011;6(5):E1-E5. doi:10.1002/jhm.703 Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628-1635. doi:10.1056/NEJMoa022963 Buggey J, Mentz RJ, Pitt B, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015;169(3):323-333. doi:10.1016/j.ahj.2014.12.009 Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023;329(3):214-223. doi:10.1001/jama.2022.23924
Episode 211 ... for the week June 17th, 2024, and this is what is going on in our Disney World...Phil's Trip Plans- The 60 Day mark has come for Phil's August Trip - what ADRs did he secure?- Phil walks through his current plans - we will monitor how much they change prior to the actual trip.Starts @0:59 ...EPCOT Construction is Complete ... For Now - With the completion of Communicore Hall and Plaza the remake of EPCOT has been declared complete ...- ... but then a week later walls were up at Test TrackStarts @25:51 ...DBC Resort Ranking - Results- We finally get to the conclusion of this exercise and review the results of our resort ranking analysis- We also compare our results to that of the DBC communityStarts @48:28 ...DBC Engagement: What Elements Do We Want in New Lands at WDW- The community shared their thoughts on what they want to see in any new lands at WDW, taking inspiration from Fantasy SpringsStarts @1:01:24 ...* Reminder to like, subscribe, rate, and review the DBC Pod wherever you get your podcast *Send us an e-mail! .... thedbcpodcast@gmail.comFollow us on social media:- LinkTree: https://linktr.ee/thedbcpod - Instagram: https://www.instagram.com/TheDBCPod/- Twitter: https://twitter.com/TheDBCPod- Facebook: https://www.facebook.com/TheDBCPod- YouTube Channel: https://www.youtube.com/thedbcpod- Discord Server: https://discord.com/invite/cJ8Vxf4BmQNote: This podcast is not affiliated with any message boards, blogs, news sites, or other podcasts
Bill Faeth and Kenny Bedwell delve into strategies for staying profitable amidst challenges such as decreasing average daily rates (ADRs), increasing competition, and market saturation. They emphasize the importance of adjusting pricing strategies, enhancing property features, and leveraging marketing tools to boost occupancy rates and overall revenue. The conversation also covers the significance of investment in high-quality property photography, dynamic pricing techniques, and ancillary services as means to increase profit margins. This episode not only addresses how to navigate through dropping ADRs but also highlights ways to capitalize on market trends, guest preferences, and technological tools to ensure STR business success. This episode of STRonomics is proudly sponsored by MarketMySTR.com, the leading marketing platform for STR Industries. 00:00 Introduction to STRonomics and Market My STR 01:26 Welcome Back to STRonomics: Insights from Industry Experts 01:34 Navigating the Changing Landscape of Short-Term Rentals 03:36 Strategies for Maximizing Revenue in a Competitive Market 16:09 Leveraging Photography and Additional Amenities for Increased Bookings 19:59 Wrapping Up: The Importance of Revenue and Profit Focus We handle the day-to-day tasks of your short-term rental, giving you the freedom to grow your business and focus on the things that matter most. In the dynamic landscape of short-term rentals, success lies in the details. At STR Super VAs, we bring expertise to every facet of your business, ensuring those details are meticulously managed. Click here to learn more about how you can integrate VAs into your business! https://www.strvas.com/ Watch this podcast each Thursday on our YouTube Channel: https://www.youtube.com/channel/UCnheh3vx0hT5Y7uHWhBs8kA STR Data Hosts Facebook Page Instagram: Kenny_Bedwell You can find more of Bill online at: Bill Faeth Linktree: https://linktr.ee/bfaeth?utm_source=linktree_profile_share<sid=660cbc9b-4a7e-4ed9-a654-900180b83af1 Build STR Wealth: https://buildstrwealth.com/ Instagram: @BillFaeth73 Tik Tok: @bfaeth Learn more about your ad choices. Visit megaphone.fm/adchoices
Mike, Scott, and Rikki are back today to have some fun with the Walt Disney World restaurants! We get this show topic from the BOGP Clubhouse as we were wondering what really drives guests to book the ADRs that they do. Are you looking more for the overall theme/experience of the restaurant or is it the food quality that is the most important factor? Today, we throw out various Walt Disney World restaurants and discuss if the experience is greater than, less than, or equal to the food quality! Play right along with us! Please share your thoughts over on the Discord channel at www.beourguestpodcast.com/discord. We hope you enjoy today's podcast! Please visit our website at www.beourguestpodcast.com. Thank you so much for your support of our podcast! Become a Patron of the show at www.Patreon.com/BeOurGuestPodcast. Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
Mike, Scott, and Rikki are here today answering some great listener questions! We discuss which breakfast ADR might be best for a family staying at the Beach Club that is using the Disney Dining Plan this July - Crystal Palace, Cape May Cafe, or Garden Grill, we also have a discussion as to why we are pretty sure Frozen will not be brought to the Magic Kingdom with "Beyond Big Thunder", we talk "good usage" for Quick-Service Disney Dining Plan credits around property, where to see a rocket launch on-property, and much more! Please come join the BOGP Clubhouse on our Discord channel at www.beourguestpodcast.com/discord! Thank you so much for your support of our podcast! Become a Patron of the show at www.Patreon.com/BeOurGuestPodcast. Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
How to find, analyze, and convert small boutique hotels? What are the systems and tools to use and the processes for hiring top people? Blake Dailey, a real estate investor, owner of boutique hotels, and founder of BoutiqueHotelCon, shares his knowledgeRead this entire interview here: https://tinyurl.com/yevhs2u3How long did it take you to surpass your W2 income after you started investing?It took 13 months from the time of purchase. Short-term rentals helped me achieve that goal more quickly.How do you find a small boutique hotel? How do you analyze it, including conversions, if you undertake them?Municipalities across the country are increasingly regulating short-term rentals in places like New York, Dallas, Atlanta, and Southern California. These regulations aim to protect the single-family housing market and the rental market. Hotels, classified as commercial properties, are designed for nightly rentals and thus aren't subjected to the same regulations. Authorities aren't shutting down major hotel chains like Marriott and Hilton due to the influence of hotel lobbyists. This lack of regulation provides an opportunity to invest in prime real estate in metropolitan areas or their suburbs.To find these opportunities, I seek out tired hospitality assets typically owned by Mom-and-Pop operators who often reside on-site and handle all management tasks themselves. The inefficiencies of managing a business where you both live and work can be substantial. Many of these operators are slow to adopt technology, neglect online travel agencies (OTAs), and fail to engage in marketing efforts beyond word-of-mouth referrals or basic direct booking websites. By acquiring these properties, refreshing and renovating them, and listing them on OTAs such as Airbnb, booking.com, and Expedia hotels.com, we can attract a wider range of guests. We also focus on collecting guest emails and contact information to facilitate direct marketing efforts, which can significantly increase margins by avoiding OTA fees.We target markets such as destination markets, ski towns, and beach towns. For instance, Panama City Beach attracts 17 million visitors annually. However, similar opportunities exist in various markets nationwide, including metropolitan areas. I've found success in acquiring outdated properties owned by owner-operators, improving their efficiency, updating their design, and consequently increasing their average daily rates (ADRs). Since commercial properties are valued based on net operating incomes, these improvements can significantly boost property values.Can you discuss your systems, processes, and approaches to hiring and developing your team?Investing in this asset class requires a team effort. I couldn't manage all my hotels alone, although I did gain experience managing all my short-term rentals while still involved in residential properties. I outsourced administrative tasks and guest communications to cope with increased demand. Boutique hotels generate revenue from the outset, enabling us to hire and outsource roles early on. For instance, with a property generating hundreds of thousands of dollars annually, we can afford a full property-level team, including a director of operations, operations manager, revenue manager, and guest relations team. Regarding guest check-in processes, we employ self-check-in systems for smaller properties, while larger properties with higher revenue may warrant on-site staffBlake Daileywww.instagram.com/blakejdaileywww.botiquehotelcon.com
Mike, Scott & Rikki are here today answering your Listener Questions! Today we discuss the advantages and disadvantages of using your Apple Watch vs. a MagicBand+ at around Walt Disney World. We also give some advice on how to get the most out of a VIP Tour experience that was gifted to one our our listeners (you are so lucky, Tammy!), and we also try to figure out why there are so many O'hana ADRs still available for Spring Break this year! This and much more coming your way on today's show! Please visit our website at www.beourguestpodcast.com. Thank you so much for your support of our podcast! Become a Patron of the show at www.Patreon.com/BeOurGuestPodcast. Also, please follow the show on Twitter @BeOurGuestMike and on Facebook at www.facebook.com/beourguestpodcast. Thanks to our friends at The Magic For Less Travel for sponsoring today's podcast!
© 2020-2025 Ivy Podcast Discovery LLC
